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ABSTRACT
Metastatic melanoma is responsible for almost 80% of all skin cancer-related deaths and
the incidence of people affected continues to rise worldwide. The emergence of targeted
therapy and immune-checkpoint inhibitors has improved the clinical management of
melanoma, but durable survival benefit is only seen in a minority of patients. The use of
these very expensive systemic therapies on all appropriate patients also poses a high
economic burden on health systems across numerous countries. Currently, surveillance
for treatment failure is not optimal. Thus, reliable and accurate biomarkers of patient
disease status are urgently required.
Circulating tumour DNA (ctDNA) analysis has emerged as a potential “liquid biopsy” for
melanoma. Plasma-derived ctDNA are short DNA fragments released into the
bloodstream by apoptotic tumour cells. Studies have shown that ctDNA levels in blood
correlate with tumour burden and can comprehensively capture the molecular
heterogeneity of melanoma metastases. Thus, ctDNA appears to be a viable biomarker for
monitoring treatment response and disease progression in melanoma patients. However,
further studies aimed at comparing ctDNA and current standard clinical assessments are
needed to fully define its suitability as a complementary test to guide treatment decisions.
This thesis aims to provide important information that will assist with the
implementation of ctDNA as a biomarker for melanoma in the clinical management of the
disease. This thesis is comprised of 7 chapters: a comprehensive literature review
(Chapter 1. Introduction); a materials and methods chapter (Chapter 2); 4 results
chapters (Chapter 3 – 6); and a final chapter with a general discussion of main findings
and future directions (Chapter 7. General Discussion and Future Directions).
The first chapter of the thesis includes a thorough review of the literature on ctDNA as a
potential biomarker for melanoma disease (Chapter 1). This is then followed by a detailed
description of our protocol for plasma ctDNA extraction and quantification using droplet
digital PCR (Chapter 2). Using this methodology, we evaluated the ctDNA detection rate
in untreated BRAF mutant melanoma patients, as a potential alternative to tumour
genotyping (Chapter 3), where the potential economic benefit of implementing plasma
ctDNA testing by ddPCR relative to tissue BRAF testing was also investigated.
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The study in Chapter 4 demonstrated that pre-treatment plasma ctDNA is predictive of
patient outcomes in the first-line treatment setting. However, baseline ctDNA level was
not predictive of outcomes in the second-line immunotherapy setting, especially in
patients that were pre-treated with BRAF/MEK inhibitors. Moreover, we found
preliminary evidence that patients with high pre-treatment ctDNA may benefit from
combined anti-CTLA-4/anti-PD-1 therapy.
Chapter 5 discusses the validity of ctDNA as a surveillance biomarker for melanoma. The
kinetics of ctDNA decline were found delayed in patients treated with immunotherapy
compared to those receiving MAPK inhibitors. Nonetheless, decreasing ctDNA levels
within 12 weeks of immunotherapy or BRAF/MEK inhibitors was strongly concordant
with treatment response and significantly associated with longer progression-free
survival (PFS). Furthermore, exploratory analysis of nine patients commencing anti-PD1 therapy showed a trend of high tumour mutational burden (TMB) and neoepitope load
in responders compared to non-responders.
Chapter 6 evaluates the validity of ctDNA to accurately detect disease progression using
both a retrospective and a prospective cohort of melanoma patients. The results indicated
a moderate detection rate, suggesting that more sensitive methodologies are required to
achieve a limit of detection comparable to current medical imaging.
Finally, Chapter 7 provides a general discussion of the studies covered in this thesis. It
underscores the clinical validity of ctDNA as a biomarker of prognosis and therapeutic
response in melanoma patients, while highlighting important limitations inherent to
ctDNA analysis that need to be thoroughly addressed before it can be successfully
implemented in the clinic.

USE OF THESIS
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW
1.1 Introduction
Melanoma is an aggressive cutaneous cancer responsible for the majority of skin cancerrelated deaths [1, 2]. In addition, the incidence of melanoma is increasing worldwide,
which results in significant costs to the healthcare systems [3]. Generally, patients are
considered cured after complete surgical resection of the primary tumour [4].
Nevertheless, around 20% of patients will develop metastatic disease, which is extremely
difficult to treat [5].
In the last ten years, the use of targeted therapies and immunotherapies has improved
the survival of metastatic melanoma patients. However, the low response rate to
immunotherapies and the risk of developing resistance to both targeted and
immunotherapies contribute to the sub-optimal prognosis for most metastatic patients.
Moreover, adverse side-effects associated with current immunotherapies restrict
treatment efficacy in some cases [6]. Therefore, new biomarkers are urgently needed for
personalised monitoring of the disease, with the aim to determine treatment response
and recurrence at earlier stages. This will allow optimal selection and/or timely
treatment modification to improve survival rates in patients.
Plasma ctDNA are short DNA fragments released into the bloodstream by the tumours
within a patient. Since ctDNA can be detected in the blood of melanoma patients, these
DNA fragments can be used as a “liquid biopsy”, providing critical insight into each
person’s melanoma status. Studies have previously shown that ctDNA levels correlate
with tumour burden and disease stage, characteristics that have been exploited in
different cancer types to determine the clinical value of ctDNA in monitoring clonal
evolution and identifying mechanisms of resistance [7-10]. Outcomes of these studies
have driven the Food and Drug Administration (FDA) and European Medicines Agency
(EMA) to approve the analysis of ctDNA in patients with non-small cell lung cancer
(NSCLC) to identify patients carrying a specific mutation that makes them resistant to
first-line treatment [11].
Plasma ctDNA in melanoma has been defined as a biomarker of disease status used to
monitor clonal evolution, detect the emergence of resistance to treatment and predict
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response to therapy [12-16]. Detection of BRAF mutations in plasma cfDNA has been
associated with higher disease burden and worse prognosis. Similarly, the presence of
BRAF or NRAS mutation prior to or during systemic treatment has been associated with
larger tumours, increased lactate dehydrogenase (LDH) levels, and development of brain
metastases [17]. Studies investigating circulating tumour DNA (ctDNA) have been
conducted mainly in small cohorts of patients treated with targeted therapies and only a
few studies have focused on BRAF wild-type patients treated with immunotherapy.
Constant changes in the pharmacotherapies used in melanoma have shaped an urgent
need to effectively evaluate the detection rate of ctDNA in large cohorts and assess its
proficiency to inform response to therapy and progressive disease. Further studies are
needed to compare this biomarker with current standard clinical assessments and to
assess its suitability as a complementary test that guides treatment decisions.

1.2 Cutaneous Melanoma
The skin is the largest organ in the body and serves to protect us from ultraviolet (UV)
light, injuries and infections, among other important functions [18]. The main layers of
the skin include the subcutaneous layer, the dermis, and the epidermis. The epidermis is
the outermost layer and contains three different types of skin cells: squamous cells, basal
cells, and melanocytes. Melanocytes are in the basal layer of the epidermis and are
responsible for melanin pigment production (Figure 1.1).
Image is available online at https://www.teresewinslow.com/#/skin/

Figure 1.1. Representation of normal skin anatomy. Melanocytes are present in the basal layer of
the epidermis. Retrieved from Winslow et al. [19].
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Cutaneous Melanoma is a highly aggressive skin tumour originating from the neoplastic
transformation of melanocytes. Melanoma occurs principally in the skin but may also
develop in the conjunctiva and uvea of the eye (uveal melanoma), on various mucosal
membranes with pigmented tissues, such as the gastrointestinal tract, oral or genital
membranes, meninges, and in internal organs, such as in the central nervous system [20].
1.2.1 Epidemiology
Cutaneous melanoma is the most lethal form of skin cancer responsible for approximately
80% of skin cancer deaths despite representing only <5% of all dermatological
neoplasms [21]. The incidence of melanoma is increasing worldwide, but New Zealand
and Australia continue to have the highest incidence and mortality rates [22, 23]. In
Australia, melanoma was the 3rd most commonly diagnosed cancer in 2019 and new cases
of melanoma skin cancer are estimated to increase to 16,221 in 2020 with approximately
1,375 estimated deaths [1] (Figure 1.2). In fact, the Australian melanoma health
expenditure each year is the highest in the world relative to the population [24].
Moreover, melanoma accounts for 11% of all newly diagnosed cancers [1]. The
anatomical location of the primary melanoma is commonly found in the trunk in men and
the extremities in women [25]. The location of the tumour also varies with age, being on
the trunk or extremities more commonly in younger ages, but on head and neck locations
in advanced ages [26, 27].

Figure 1.2. Age-standardised incidence rates for melanoma skin cancer 1982–2013 and agestandardised mortality rates for melanoma skin cancer 1968–2014, by sex, in Australia. Retrieved
from the AIHW 2017 [2].
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1.2.2 Aetiology
Sun exposure is a major risk factor associated with cutaneous melanoma formation. UV
radiation induces the formation of mutagenic cyclobutane pyrimidine dimers. A
significant number of melanoma-associated genes bear UV-induced signature C>T
transition mutations in cellular DNA [28-32]. Melanoma also has the highest median
number of somatic mutations across all human cancer types [33].
Trends in melanoma incidence show that Caucasian race, male gender, and older age are
characteristics associated with an increased risk of developing melanoma [34]. Also, fairskinned individuals with red or blond hair and many freckles are more likely to suffer
from the disease [35, 36]. Having a higher number of benign melanocytic naevi, atypical
naevi or giant congenital naevi also increases the risk of developing melanoma [37, 38].
Other host factors such as a personal history of melanoma or non-melanoma tumours,
including other skin cancers, can increase the risk of developing melanoma [39-41].
Moreover, a weak immune system or having a disease that weakens the immune system,
increases the cancer risk, with a higher incidence of cutaneous melanoma in patients after
organ transplantation proposed to be due to medical immunosuppression [42].
Genetic predisposition is also a factor involved in melanoma development. About 10% of
all melanomas are estimated to be due to hereditary susceptibility [43]. Since William
Norris [44] first suggested that melanomas have a hereditary component, the knowledge
of melanoma genetics has advanced significantly. It is now known that having a family
history of melanoma increases the risk 1.74 times compared with a negative family
history of the disease [45]. Inherited genetic risk factors can be classified by their
penetrance and prevalence [46].
Rare but highly penetrant genetic mutations in CDKN2A and CDK4 genes are commonly
found in high-risk melanoma families [47]. These genes are involved in cell-cycle
regulation and melanocyte senescence. As an example, the CDKN2A gene located on
chromosome 9p21.3, encodes two proteins. p14ARF and p16INK4A, which control cell
cycle entry at the G1 checkpoint and stabilise p53 expression [48]. Low melanoma
penetrance mutations present in the general population, often referred to as single
nucleotide polymorphisms (SNPs), have also been detected in genes involved in hair and
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skin pigmentation, such as MC1R, ASIP, TYR and TYRP1 [49-52]. In addition, SNPs in BAP1,
POT1, ACD, TERF2IP, and TERT are also considered risk genes for inherited melanoma
[53].
1.2.3 Diagnosis
The first step in melanoma diagnosis is the visual characterisation of suspicious lesions.
Nonetheless, diagnosis of melanoma is often complicated by the resemblance of early
stage melanoma to naevi, which are chronic lesions found in the skin or mucosa [54].
While naevi are often considered benign, more than 20% of malignant melanomas arise
from pre-existing naevi [55]. Visual characteristics of a transformed mole can be
identified via the “ABCDE criteria”: Asymmetry, a Border that is irregular, Colour that is
uneven, a Diameter longer than 6 millimetres and, a shape, size or colour that is Evolving
(Figure 1.3). Other early signs of a malignant change are itching, ulceration or bleeding.
By contrast, nodular melanomas do not follow these criteria. They have their own "EFG
criteria"; the lesion is Elevated above the surrounding the skin, the nodule is Firm to the
touch and Growing in size.
Image is available online (Figure 5) at https://www.cancer.gov/types/skin/hp/skingenetics-pdq

Figure 1.3. Melanomas with characteristic asymmetry, border irregularity, colour variation and
large diameter. Retrieved from the National Cancer Institute [56].

The majority of abnormal lesions/naevi/moles are primarily detected through skin
examination and assessed using dermoscopic tools that can differentiate melanoma from
other types of carcinoma or benign lesions [57]. Some of the diagnostic techniques
available for better identification of skin cancer include; total body photography [58],
multispectral imaging, confocal scanning laser microscopy, ultrasound imaging [59],
magnetic resonance imaging [60], and optical coherence tomography. A histological
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examination of a tissue biopsy from a suspected lesion is necessary to confirm melanoma
diagnosis and tumour staging. The histopathological criteria of melanoma are based on
abnormal characteristics of the lesion such as ulceration, the extent and penetrance of
the tumour, and the mitotic rate of the cells in the lesion.
The discovery of histologic markers that uniquely identify melanocytes in melanoma has
aided melanoma diagnosis. The most commonly used markers are S100 [61], MART1/Melan-A [62], HMB-45 [63, 64], SOX-10 [65] and MC1R [66]. Currently, a combination
of multiple positive histologic markers and histopathologic criteria provides the most
reliable method of diagnosis. If melanoma cells are detected in a lesion, the spread of the
disease will be further assessed, to stage the melanoma.
1.2.4 Staging of melanoma
To determine the optimal treatment strategy and the prognosis of a patient with
melanoma, staging of the biopsied material is needed. The American Joint Commission on
Cancer (AJCC) updated the melanoma classifications in 2017 [67] using the most
significant prognostic values as shown in Table 1.1. The clinical staging of melanoma is
based primarily on the micro-staging of the excised tumour and the clinical and
radiological examination of the regional lymph nodes and distant organ involvement.
Patients are then classified into five main groups. In patients with stage 0 (in situ
melanoma), melanoma is confined to the epidermis and has not invaded deeper skin
layers. Patients with clinical stages I and II, are those with primary melanoma and no
evidence of metastases. Stage III is indicated for patients with evidence of regional lymph
node metastases. Lastly, stage IV melanoma patients are those that have been diagnosed
with one or more distant metastases [68]. Pathological staging includes micro-staging of
the primary melanoma and pathological information about the regional lymph nodes
after lymph node biopsy. Both clinical and pathological staging are important in
melanoma diagnosis and treatment decisions.
The TNM classification is used to stage patients based on the extent of the primary
tumour (T), the presence or not and the extent of regional lymph node metastases and
non-nodal locoregional sites, such as in-transit, satellite and/or microsatellite metastases
(N), and the presence or absence of distant metastases (M) [69].

26
Table 1.1. Classification of the pathological stage and the main features related to melanoma
staging [67, 70]. MN=matted nodes; ISM=In-transit, satellite or microsatellites.
TNM

Breslow’s
Thickness
(mm)

Ulceration

No.
Positive
Nodes

Nodal
Type

Metastasis

0

Tis

-

-

0

-

IA

T1a

<0.8

No

0

T1b

<0.8
0.8 - 1.0

Yes
Yes/No

IB

T2a

>1.0 - 2.0

IIA

T2b

Pathologic
Stage

Survival (%)
5 years

10 years

-

≥99

≥99

-

-

99

98

0

-

-

99

96

No

0

-

-

96

92

>1.0 - 2.0

Yes

0

-

-

93

88

T3a

>2.0 - 4.0

No

0

-

-

94

88

IIB

T3b

>2.0 - 4.0

Yes

0

-

-

86

81

T4a

>4.0

No

0

-

-

90

83

IIC

T4b

>4.0

Yes

0

-

-

82

75

IIIA

N1a-

<0.8
0.8 - 1.0
>1.0 - 2.0
>1.0 - 2.0
>2.0 - 4.0

93

88

83

77

69

60
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N2a
IIIB

IIIC

IIID

IV

N1a
N2b
N1b
N1c
N1b
N1c
N2b
N1a N2c
N2b
N2c
N3b
N3c
N2c
N3a
N3b
N3c

Yes/No
Yes
No

-

-

<0.8 - >1.0 -2.0

Yes/No

>4.0

Yes

-

-

1

Occult

-

2-3

Occult

-

1-3

Any

1
0
1
0
2-3

Apparent
Apparent
≥1 App.

1-3

Any

2-3
1
≥4
≥2
1
≥4
≥4
≥2

≥1 App.
Any
≥1 App. MN
≥2 App. MN
Any
Occult
≥1 App. MN
≥2 App. MN

ISM
ISM
ISM
ISM
ISM
ISM
ISM
ISM

Any

Any

<0.8 - >2.0 -4.0

Any

N≥1

>2.0 - 4.0
>4.0

Yes
No

1- ≥4

N3a

>4.0

Yes

≥4

Occult

-

N3b

>4.0

Yes

≥4

≥1 App. MN

ISM

N3c

>4.0

Yes

≥2

Occult;
Apparent;
Any MN

M1a

Any

Any

Any

Any

Skin

n/a

n/a

M1b

Any

Any

Any

Any

Skin; Lung

n/a

n/a

M1c

Any

Any

Any

Any

Other; Non-CNS Visceral

n/a

n/a

M1d

Any

Any

Any

Any

Other; CNS Visceral

n/a

n/a

The N category defines the number of clinically occult or clinically apparent regional
nodes or macro-metastatic nodes determined by standard immunohistochemical
staining using melanocytic markers. The presence of intra-lymphatic metastases
including the presence or absence of satellites or in-transit metastases are also taken into
consideration in this category. Regional nodal metastasis is defined as a disease confined
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to one nodal basin, while patients with distant nodal metastases will be classified as
having M stage disease [69].
The M category defines the presence of distant metastases in the skin, subcutaneous
tissue, or distant lymph nodes or organs. Importantly, based on the anatomic sites of
metastasis, patients are assigned into 4 M subcategories: M1a, M1b, M1c, and M1d.
Patients with distant metastasis to the skin, subcutaneous tissue, muscle, or distant
lymph nodes are categorized as M1a. Patients with metastasis to lung (with or without
M1a disease) are categorized as M1b. Patients with metastases to any other visceral
site(s) (excluding central nervous system (CNS) disease) are designated as M1c, while
patients with metastases to the CNS are designated as M1d.
Cutaneous melanomas are also subdivided into several subtypes, based on common
anatomical locations and different patterns of growth. Superficial spreading melanoma is
the most frequent, followed by nodular melanoma, acral lentiginous melanoma and
lentigo maligna melanoma [71].
1.2.5 Genetic and histopathological changes in melanoma development
As explained above, both genetic predisposition and exposure to environmental agents
are risk factors for melanoma development. It is important to highlight that melanocyte
malignant transformation involves the progressive accumulation of mutations in genes
that are involved in cell-cycle control, proliferation, differentiation, and cell death [72],
until finally, melanoma cells acquire the ability to initiate and sustain angiogenesis. This
process, by which melanocytes progress to a malignant phenotype through several steps,
is known as melanomagenesis [73] (Figure 1.4).
Based on the pattern of the most prevalent and significant mutated genes, melanomas
can be classified into four genomic sub-types: mutant BRAF, mutant NRAS, mutant
neurofibromin type 1 (NF1), and triple wild-type (WT; Figure 1.5) [74]. Molecular
classification of melanomas is important as it can guide treatment strategies.

28
Image is available (Figure 2) at https://www.nejm.org/doi/full/10.1056/NEJMra052166

Figure 1.4. Biologic events that take place in melanoma progression. The benign nevus
commences a dysplastic transformation, through radial and vertical growth until the metastatic
phenotype arises. Adapted from Miller et al. [5].

The RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signal transduction
pathway is one of the most important pathways in the origin and progression of
melanoma. BRAF is a member of the RAF family of serine-threonine kinases, along with
ARAF and CRAF (also called RAF1). Mutations in the BRAF gene have been described in
40-60% [75, 76] of all melanoma cases. Among mutations in the BRAF gene,
approximately 80% of the mutations result in the substitution of glutamic acid (E) for
valine (V) in codon 600, known as the BRAF V600E mutation. About 16% of mutations in
this gene result in a lysine (K) substitution at the same BRAF V600K codon, and 3% result
in an aspartic acid (D) or arginine (R) substitution that produces a V600D/R codon [77].
These last two mutant forms of BRAF tend to be present in melanomas arising in older
patients [78]. All of these mutations occur as early events in melanomagenesis and result
in a mutant protein that is constitutively active in the cell without the need for activation
signals. The consequence is uncontrolled proliferation and resistance to apoptosis.
Nevertheless, the presence of BRAF mutations in 80% of benign naevi suggests that
mutational activation of the MAPK pathway is a critical step in melanocytic
transformation but alone is insufficient for melanoma tumourigenesis [79].
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Mutations in the NRAS gene are present in approximately 15 to 20% of all cutaneous
melanomas [80]. Commonly, NRAS mutations occur in codon 61, resulting in replacement
of a glutamine residue by an arginine (Q61R) or lysine (Q61K) in the protein. However,
other forms of NRAS mutations result in a substitution of glutamine at position 61 by
leucine (Q61L) or histidine (Q61H) or substitution of glycine at position 12 or 13 by
aspartic acid (G12D/G13D). Mutated NRAS results in constitutive activation of the MAPK
signalling pathway resulting in increased cell proliferation and advancement of tumour
growth. Tumours that carry NRAS mutations represent a distinct subpopulation from
mutant BRAF melanomas, since BRAF and NRAS mutations are generally mutually
exclusive [81, 82]. Together, NRAS and BRAF mutations are present in about 70% of the
most common types of melanoma [74].
NF1 is the third most commonly mutated gene in melanoma and is present in up to 46%
of BRAF and NRAS wild-type melanomas or ~12-18% of all melanomas. NF1 shows a high
frequency of non-silent exonic mutations and a low frequency of synonymous or intronic
mutations but there are no hot spot mutations in NF1 [83]. This tumour suppressor gene
encodes for a direct negative regulator of RAS, which cooperates with mutated BRAF in
melanomagenesis [84].
Image is available (Figure 1 - middle section of A) at https://doi.org/10.1016/j.cell.2015.05.044

Figure 1.5. Frequency and mutation subtypes associated with melanoma. Retrieved from the
Cancer Genome Atlas [74].

Another important genetic alteration present in melanoma is found on a wellcharacterised tumour-suppressor, the phosphatase and tensin homolog (PTEN) gene.
The encoded protein is a key initiator of the PI3K signalling pathway. Somatic PTEN
mutations or deletions have been identified in 10-30% of melanomas [74, 85]. Loss of
PTEN frequently coexists with BRAF mutations, but not with mutant NRAS, which can
activate the PI3K pathway independently.
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The Ras-related C3 botulinum toxin substrate 1 (RAC1) gene encodes for an RHO GTPase
protein which plays a key role in cellular cytoskeleton organization. Dysregulation of
RAC1 leads to cell proliferation and suppression of antitumor immune responses [86]. A
recurrent mutation at codon 29 (P29S) of RAC1 that leads to a proline-to-serine
conversion has been identified in 5% to 9% of melanomas.
The telomerase reverse transcriptase (TERT) gene encodes for a catalytic subunit of the
holoenzyme telomerase, which sustains telomere length and chromosomal stability.
Reactivation of the TERT gene enables cells to overcome replication-induced senescence,
a critical step in tumour initiation. There are two recurrent mutations, located within 100
base pairs of the TERT transcriptional start site on chromosome 5; cysteine-to-threonine
mutations at codon 228 (C228T) and codon 250 (C250T). These mutations are consistent
with an ultraviolet signature (C>T or CC>TT), thus implicating a role for ultraviolet
radiation in their induction. These mutations have been identified in sporadic primary
melanomas (33%), metastatic melanomas (85%), and melanoma cell lines (76%) [87]. In
addition, 55% of melanomas have TERT mutations co-existing with BRAF or NRAS
mutations [88].
Melanomas may also carry mutations that activate the KIT receptor protein tyrosine
kinase, tumour protein 53 (TP53) or cyclin-dependent kinase inhibitor 2A (CDKN2A). The
KIT gene is located on the long (q) arm of chromosome 4. Most KIT mutations are located
in exon 11, which encodes for the juxtamembrane domain, and in exon 13, which encodes
for a kinase domain [89]. Mutations in TP53 are prevalent in approximately 20% of
melanomas [90] and CDKN2A, which encodes for the p16INK4A protein, is found mutated
in approximately 30% to 40% of familial melanomas [91, 92]. Altogether, studies have
shown that BRAF, CDKN2A, NRAS and TP53 are significantly mutated in cutaneous
melanoma; BRAF, NRAS and NF1 in acral melanoma, and SF3B1 in mucosal melanoma
[93].
1.2.6 Progression
Metastatic melanoma can be distinguished as either a local recurrence, in-transit
metastasis, nodal metastasis and/or distal metastasis, based on the morphological
characteristics and location. Local recurrence is defined as a recurrence of melanoma
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within 2 cm of the surgical scar of a primary melanoma [94]. This recurrence can result
from either the extension of the primary melanoma or from the spread via lymphatic or
haematogenous vessels [95]. In-transit metastasis is defined as melanoma deposits
within the lymphatic vessels located more than 2 cm from the site of the primary
melanoma. Nodal metastasis involves the spread of tumour cells into the lymph nodes.
Haematogenous spread of metastatic melanoma results in the development of distal
metastasis [96].
A variety of sophisticated imaging techniques are now used to follow and evaluate
patients with melanoma, including chest radiographs, regional nodal ultrasound imaging,
computerised tomography (CT) scans, positron emission tomography (PET), PET/CT
scans, and brain/spine and hepatic magnetic resonance imaging (MRI) to detect nodal
disease and distant metastases [68, 97]. Among all these modalities, PET scans have
shown an improved performance in depicting metastatic lesions over conventional
imaging modalities, such as CT has been commonly described in the literature [98, 99].
In addition, LDH blood levels have been considered an important prognostic marker for
patients with stage IV disease [100]. However, LDH levels are highly affected by other
normal biological processes including inflammation and tissue damage. Therefore, new
biomarkers are required to identify patients likely to develop distant metastases.
1.2.7 Treatment and prognosis
The standard treatment for in situ and primary melanoma is wide local excision (WLE) of
the skin and subcutaneous tissues around the melanoma. Surgical removal of melanoma
offers the best chance for a complete cure and is usually successful in patients categorised
as stage 0, I and stage II. Most patients do not need either radiotherapy or chemotherapy
since the tumour is still localised and there are no other existing metastases. However,
greater tumour thickness is associated with an increased risk of local recurrence [101].
WLE is the treatment of choice in local recurrences, with consideration given to adjuvant
therapy in some situations [68], since there is an increased risk of systematic or regional
metastasis.
Currently, sentinel lymph node biopsies are carried out in patients with melanomas
thicker than 1mm, or >0.8mm if the tumour is ulcerated [67, 102]. If the result is positive,
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the patient will be diagnosed with melanoma stage III. Since patients with positive lymph
nodes are at high risk of systemic dissemination, a therapeutic lymph node dissection
may be considered. However, the MSLT-I study together with the Cochrane Review found
no improved melanoma-specific survival for patients with intermediate or thick
melanomas treated with a sentinel lymph node biopsy [103, 104]. In addition, adjuvant
treatment with targeted therapies and immunotherapies is the standard of care due to
their proven increase in survival and delayed disease recurrence [105, 106].
In regards to prognosis, the main clinical and histopathologic predictors of outcome are
Breslow’s thickness, the presence of ulceration, the sentinel lymph node status [107] and
the presence of distant metastases.
The choice of therapy for the management of unresectable or metastatic melanoma
depends on the number of lesions present within a patient, as well as the anatomical
location, and size of the lesions. Treatment for metastatic melanoma aims to control the
melanoma and to relieve any symptoms, with curable intentions. When surgery is not
possible, treatments such as targeted therapies, immunotherapy, chemotherapy,
radiotherapy and diverse clinical trials of these and other new drugs individually or in
combination are available. Since 2011, treatment combinations using targeted therapy
and/or immunotherapy have revolutionised the clinical management of melanoma
patients, improving the length of survival of patients with stage III or stage IV melanoma
[108-110].
Targeted Therapy
Since the discovery of the presence of activating mutations in the BRAF oncogene in
approximately 50% of melanomas [75], there has been notable progress in the
development of targeted therapies for unresectable and metastatic melanoma of patients
carrying this mutation [111]. The FDA approved the use of BRAF inhibitors vemurafenib,
dabrafenib and encorafenib as first line therapy for BRAF positive metastatic or
unresectable melanoma [112, 113].
The great success of BRAF inhibitors in some patients and at the same time, the disease
relapse in other patients treated with BRAF inhibitors, prompted the development of
MEK inhibitors to further inhibit the MAPK signalling pathway at the next downstream
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MEK1/2 activation point. Nowadays, the FDA approved MEK inhibitor trametinib, is less
commonly indicated as a monotherapy, being used more commonly in combination with
dabrafenib. The other FDA-approved MEK inhibitor, cobimetinib, is indicated for use in
combination with vemurafenib [114]. Additional MAPK targeted drugs have been
developed, such as BRAF inhibitor, encorafenib and MEK inhibitor, binimetinib. Results
from an open-label phase III COLUMBUS trial showed that encorafenib and binimetinib
combination offer longer median PFS and OS than vemurafenib monotherapy [115].
As a result of the positive outcomes from the clinical trials involving these combination
therapies (Figure 1.6), BRAF/MEK-inhibitor combination therapy is the standard-of-care
for BRAF-mutant metastatic melanoma.
While targeted therapies are effective in most patients (~65%) [116], unfortunately, the
impressive initial tumour shrinkage is relatively short-lived and acquired resistance
occurs in a high proportion of cases (58%) [117-119]. Another disadvantage of this type
of therapy is that significant toxicities are associated with BRAF inhibitors [120] and
combination therapies [121, 122]. Combination dabrafenib/trametinib regimens are
associated with high fever whereas vemurafenib/cobimetinib combination therapy
causes cutaneous and gastrointestinal adverse events [123]. Similarly, common adverse
events with encorafenib/binimetinib included nausea, vomits, muscle spasms and
altered liver function [124].
Immunotherapy
Immunotherapy aims to strengthen the anti-tumour immune response in patients with
stages III or IV malignant melanoma. In 2011, the FDA approved the use of immune
checkpoint inhibitor, ipilimumab for unresectable metastatic melanoma. This antibody
binds to the cytotoxic T-lymphocyte antigen 4 (CTLA-4) on tumour cells and blocks its
activity, allowing immune cells to target the melanoma cells. Unfortunately, the patient
response rate is low (11.9%) and immune-related adverse effects, such as, dermatitis,
diarrhoea and colitis, are severe and common [125].
Alternate immune attenuating checkpoints have been identified including the interaction
between programmed death-1 factor (PD-1) with its ligand (PD-L1) on diverse cells, such
as, antigen-presenting cells and tumour cells. This interaction is now routinely targeted
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for the treatment of metastatic melanoma [110, 126]. Pembrolizumab and nivolumab are
anti-PD-1 antibodies approved by the FDA for the treatment of advanced melanoma in
BRAF negative melanomas [127, 128] or as a second-line therapy in patients that acquire
resistance to BRAF inhibitors. Although the toxicities associated with these agents are
severe, the frequency is lower than for ipilimumab. The objective response rates of
melanoma patients to nivolumab, and pembrolizumab are 43.7% and 33.7% respectively
[109, 129].
Although immunotherapies have shown long-lasting effects in a moderate proportion of
metastatic melanoma patients, approximately one-fourth/one-third of the patients will
eventually relapse after showing initially an objective response to treatment [130].
Currently, much effort is placed on developing different therapeutical strategies to
transform immunologically “cold” tumours into “hot” tumours. These approaches involve
combination therapies [109, 131, 132] and the use of targeted therapy plus
immunotherapy. Clinical trials of combination immune therapies [133-136] which
compare the efficacy of single-agent nivolumab or ipilimumab versus ipilimumab plus
nivolumab demonstrate increased response rates and overall survival in the combination
therapy (Figure 1.6).
The increase in overall survival offered by immunotherapy and targeted therapy
generated considerable interest to investigate these therapeutic agents in the
neoadjuvant and adjuvant settings. Neoadjuvant therapy would allow curative surgical
resection in melanoma patients with locally advanced disease. The use of neoadjuvant
therapy is currently an active field of research, especially for patients with stage III that
are at high risk of relapse. Numerous completed and ongoing trials are investigating the
use of immunotherapies in the neoadjuvant setting.
Systemic immunotherapies have also shown a positive effect in stage III and IV postsurgery patients as an adjuvant treatment. Recent studies have demonstrated that
adjuvant ipilimumab following resection of stage III disease improves PFS and OS rates
at 5 years versus placebo (65% and 54% respectively).
However, in the ipilimumab cohort, grade 3 or 4 adverse events occurred in 41.6% of
patients, together with 5 deaths (1.1%) [137]. Studies comparing ipilimumab with
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nivolumab for resected stage III and IV disease, identified nivolumab as more effective
and less toxic than ipilimumab [106]. However, further studies are needed to identify the
best adjuvant therapy, as well as the dose and the duration of treatment that will benefit
most patients.
Image is available https://pubmed.ncbi.nlm.nih.gov/28756137/

Figure 1.6. Summary of A) progression-free and B) overall survival by Kaplan–Meier analysis
across clinical trials in patients with advanced-stage melanoma. Retrieved from Ugurel et al.
[138].

Combinations of BRAFi and immunotherapy
Since BRAF-targeted therapy is associated with favourable effects in the tumour
microenvironment [139-141], it was hypothesised that multi-modality treatment
approaches that combine targeted therapies and immunotherapies might be of clinical
value. Clinical trials comprising targeted therapies together with immunotherapies are
also now underway, to explore the safety of the triple-combination of BRAF, MEK, and
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PD-1 or PD-L1 inhibitors (CD-ON-MEDI4736-1161; KEYNOTE-022; COMBI-I; GP28384/
TRILOGY). Initial data suggests that this combination is well tolerated, and response rates
are similar to those observed with BRAF-MEK inhibitor combinations [142-146]. Further
investigations will provide a more extensive understanding of the clinical utility of these
therapies and their long-term efficacies.
Intratumoral Immunotherapy
More recently, melanoma treatments may include T-VEC, a genetically modified herpes
virus that replicates in carcinogenic cells when directly administrated into tumours. This
oncolytic virus induces the production of granulocyte-macrophage colony-stimulating
factor, improving the antigen presentation by macrophages, and enhancing a broader
immune response to tumour antigens [147].
T-VEC is the most recent agent approved by the FDA for local treatment of advancedstage, unresectable cutaneous, subcutaneous, and nodal lesions in patients with
recurrent melanoma after surgery. Preliminary data from clinical trials indicate that
lower toxicities and higher response rates are observed in patients treated with T-VEC in
combination with ipilimumab (~50%) [148] or pembrolizumab (~46%) [149]. Ongoing
trials are now comparing T-VEC alone or in combination with checkpoint inhibitors in
advanced melanoma [150].
1.2.8 Melanoma blood-based biomarkers
Current therapeutic options for late stage melanoma disease are more effective in
patients with a lower disease burden [151, 152]. The ability to identify melanoma at
earlier stages or to recognise signs of disseminating disease prior to overt metastatic
disease would be of significant clinical benefit. In addition, the rapidly evolving clinical
landscape of melanoma therapy would be dramatically improved by the development of
reliable and accurate biomarkers to provide accurate molecular classification and
prognostication, and to monitor patient surveillance, during and/or post-treatment
[153].
Currently, there are limited blood-based or tissue-specific biomarkers that are used for
the clinical assessment of melanoma. One such marker routinely used to determine
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prognosis in later disease stages is LDH, now incorporated into the TNM staging of
melanoma [154]. However, the sensitivity of this marker is reduced during progression
because it has a narrow dynamic range and its increase can be associated with nonspecific inflammatory conditions [155].
MicroRNAs (miRNAs) present in the blood of melanoma patients can discriminate
between healthy individuals and cancer patients [156]. Moreover, miRNA 150-5P [156]
and miRNA 206 [157] have been found to predict melanoma patients with shortened PFS.
Melanoma exososomal proteins, such as tyrosinase-related protein 1 (TYRP1),
tetraspanin CD63 and caveolin-1 have been found elevated in patients with advanced
stage melanoma [158] and related to the development of resistance to treatment [159,
160].
Circulating tumour cells (CTCs) have also been indicated as a prognostic marker for
melanoma [161-164], with the presence of these cells in the blood correlates with poor
prognosis and short survival despite systemic treatment [165-167]. Additionally,
heterogeneous CTCs have been identified with distinct populations shown to respond
differently to targeted and immune therapies [168-170].
Although the prognostic utility of novel melanoma biomarkers, such as miRNA,
exosomes, and CTCs have been evaluated with promising results, none have been utilised
in the clinic to date for melanoma. Therefore, the ability to measure disease burden and
treatment responses is limited and there is a need for biomarkers that are sensitive or
specific enough to be beneficial for early detection of melanoma and prediction of
treatment response and, to monitor melanoma and assess therapeutic responses are
required.

1.3 Circulating tumour DNA (ctDNA)
The presence of fragments of cell-free nucleic acids (cfDNA) in human blood was first
described by Mandel and Métais in 1948 [171]. These cfDNA are short nucleic fragments
(~166 bp) found in plasma, serum, urine, cerebrospinal fluid, pleural fluid, and saliva
[172-174]. It is thought that cfDNA is released as a result of cell apoptosis and/or necrosis
and may also be released by active secretion (Figure 1.7).
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In healthy individuals, cfDNA is released from apoptotic and necrotic cells into the
bloodstream to reach concentrations that range from 1 to 10 ng ml−1 in plasma [175-177].
However, these concentrations appear to be raised in patients with cancer, acute trauma,
cerebral infarction or, as a result of exercise, transplantation and, infection, among other
factors. In addition, cfDNA analysis provides “real-time” information about the mutations
present in the tumour(s) since its half-life is between 15 minutes to 2.5 hours in
circulation before it is cleared via degradation by the liver and kidney [178].
Image is available https://doi.org/10.1038/nrclinonc.2013.110

Figure 1.7. Analysis of cfDNA from the blood. cfDNA is released from cells undergoing apoptosis
or necrosis. Retrieved from Crowley et al. [179].

Stroun and colleagues reported in 1989, that a proportion of cfDNA in the plasma of
cancer patients originates from cancer cells [180]. However, only five years later, mutant
KRAS sequences were first reported to be detected in the cfDNA of patients with
pancreatic cancer, with the KRAS mutation matching that found in the patient’s tumour
[181, 182], thus confirming that the mutations found in cfDNA are of tumour origin. Those
tumour-specific DNA fragments were termed “circulating cell-free tumour DNA” (ctDNA)
and are found to be shorter (134 - 144bp) than most cfDNA fragments [183].
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Circulating tumour DNA (ctDNA) is one marker with great potential to provide
information pertaining to treatment response early during treatment. Plasma ctDNA is
derived from tumour cells that undergo apoptosis and so molecular characterisation
provides information that can guide therapeutic decisions. In addition, ctDNA levels are
indicative of tumour burden in patients with advanced melanoma and may similarly
indicate residual localised disease.
Notably, at any one-time point, the blood of cancer patients contains ctDNA from multiple
tumour sites, allowing faster, more accurate/complete analysis than that of individual
tumour biopsies, which are from selected tumour sites. The short half-life of ctDNA [184]
and the associated low risk of repeated collections enables the use of this liquid biopsy
for detection of residual disease and to monitor cancer burden in response to a given
therapy. In addition, genomic analysis of the ctDNA allows for early cancer detection and
diagnosis (Figure 1.8). During the last decade, the development of more sensitive
detection methods has allowed the study of this minimally invasive “liquid biopsy” for
improved cancer management and monitoring.
Image is available https://pubmed.ncbi.nlm.nih.gov/28233803/

Figure 1.8. Applications of circulating tumour DNA analysis during the course of disease
management. Retrieved from Wan et al. [185].

1.3.1 ctDNA detection methods
The detection in ctDNA from the blood of melanoma patients poses a significant
challenge. Sensitive methods are required to detect low amounts of ctDNA, quantify the
number of mutant fragments of ctDNA, and discriminate between normal cfDNA and
tumour ctDNA. The analysis of ctDNA can be separated into two approaches based on
whether the objective is to monitor specific genes or mutations in a targeted approach or
to examine all genes in an untargeted approach (Table 1.2).
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Table 1.2. Technologies for detecting circulating tumour DNA (ctDNA). Adapted from Elazezy et
al. [186].
Method

Platform

Sensitivity

Specificity

Input

Targets

Type of
alteration

TAm-Seq

0.02%

99.9997%

0.920 ng

Panel

Known mutations

Safe-SeqS

0.1%

98.9%

3 ng

Panel

FASTSeqS

>10%

80%

510 ng

Panel

CAPP-Seq

0.004%

>99.99%

32 ng

Panel

MCTA-Seq

0.25%

89%

7.5 pg

Panel

>0.4%

100%

>0.1%

99.6%

ddPCR

0.1%

BEAMing

NGS

BiasCorrected
Targeted
NGS
MultiplexPCR NGS

Known mutations
and CNV
Genome-wide copy
number changes
Known mutations,
CNV, and
rearrangements
Known
methylation sites

Panel

Known mutations,
CNV, and
rearrangements

250 ng

Panel

Known mutations

100%

25 ng

1 to 3

Known mutations

0.01%

100%

1 ng

1 to 20

Known mutations

AS-PCR

1%

98%

3–
50 ng

1

Known mutations

AS-NEPBPCR

0.1%

100%

20 ng

1

Known mutations

(PNA-LNA)
PCR clamp

0.1–1%

79%

30 ng

1

Known mutations

(COLDPCR)

0.1%

94.9%

1–
10 ng

1–3

Known mutations

MS-PCR

0.62%

100%

SERS

0.1%

100%

UltraSEEK

0.1%

100%

Digital-PCR

Real-Time
PCR

Massspectrometry
technology

20–
100 ng
5 ng
9 pg4.2 ng

Limitations
Detects only known
mutations
Less comprehensive
than WES
Low sensitivity and
specificity
High cfDNA input;
detects only known
mutations
Low sensitivity and
high cfDNA input
Known mutations.
Detects only known
mutations
Detects specific
genomic loci; limited
in multiplexing
Detects only known
mutations; no
multiplexing
Low sensitivity;
detects known
mutations
Detects only known
point mutations
Low specificity;
detects only known
point mutations

3 to 10

Known
methylation sites
Known mutations

Detect limited
genomic loci; limited
in multiplexing
Detects only specific
CpG islands
Limited loci

Up to 40

Known mutations

Limited loci

1

Assays that target individual mutations can achieve high sensitivity using a relatively
simple workflow. Allele-specific PCR methods have been applied for the detection of hotspot mutations in melanoma [187]. Similarly, a melanoma-specific panel was developed
based on UltraSEEK technology [188]. Nevertheless, the most common methods to
quantify plasma ctDNA are based on detection of single melanoma mutations by droplet
digital PCR (ddPCR) [189] and BEAMing (beads, emulsion, ampliﬁcation and magnetics)
[190].
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Due to its high sensitivity and specificity, ddPCR has been recognised as one of the most
accurate and reliable tools to examine genetic aberrations in a wide variety of cancers
[191]. Studies assessing the validity of ctDNA as a biomarker of disease status in stage IV
melanoma, show that the sensitivity of ddPCR appears to be similar to the BEAMing
method, with ctDNA detection values ranging from 73% to 89% [12, 14, 17, 192, 193].
Since around 70% of melanomas harbour BRAF V600 or NRAS Q61 mutations, targeted
approaches for ctDNA analysis are highly efficient in most melanoma cases. However,
patients that are wild-type for BRAF and NRAS (approximately 30% overall) are more
challenging to monitor since new, personalised targets have to be identified. While the
sensitivity of ddPCR and BEAMing allow the detection of low frequency, specific
mutations, they are most suited for investigating a small number of pre-identiﬁed targets.
The development of technologies based on next-generation sequencing allows a broader
study of the genome, enabling the monitoring of multiple tumour-specific mutations in a
single assay. Targeted sequencing can be used to study small regions, such as individual
exons, or a larger number of loci, expanding our ability to detect multiple genes of interest
[194-197] (Table 1.2).
1.3.2 ctDNA as a biomarker of disease status in metastatic cancers
Various studies have shown that ctDNA levels correlate with tumour burden and disease
stage in different cancer types [195, 198-201]. A study focused on comparing tumour
volume with ctDNA levels in ovarian cancer, reported that ctDNA levels and disease
volume were significantly correlated. In addition, the extent of the decrease in ctDNA
levels after chemotherapy initiation was significantly associated with time to progression
[202]. In patients with colorectal and breast cancer, detectable or increased ctDNA
detection is a biomarker of worse survival compared with undetectable or decreasing
ctDNA levels [195, 203].
Studies have also demonstrated that ctDNA can be used to monitor clonal evolution and
identify mechanisms of resistance to treatment [7-10]. Serial ctDNA analysis in patients
with colorectal cancer demonstrated the positive selection of KRAS mutant clones during
EGFR blockade, and a later decline in the ctDNA levels from KRAS mutant clones upon the
withdrawal of anti-EGFR therapy [204, 205]. In patients with NSCLC undergoing

42
treatment with EGFR inhibitors, resistance-conferring mutations emerged in plasma
ctDNA prior to clinical progression determination [206, 207]. Studies in metastatic breast
cancer comparing the sensitivity of ctDNA detection versus the widely used cancer
antigen 15-3 biomarker showed ctDNA detection in 97%, in comparison with CA 15-3
detection in only 78% of 30 women with metastatic breast cancer [195]. Similar results
were found in colon cancer, where ctDNA anticipated tumour recurrence earlier than the
carcinoembryonic antigen biomarker [208].
Taken together, this evidence led the FDA and the EMA to approve the use of ctDNA
analysis in non-small cell lung cancer (NSCLC), to detect the tyrosine kinase resistant
clone EGFR p.T790M mutation allowing the early identification of patients that will
benefit from second-line drugs [11]. Current FDA and EMA recommendations for the use
of ctDNA in NSCLC, state that, if liquid biopsies are performed in advance of a tumour
biopsy, ctDNA detection may abrogate the need for tissue biopsy, but if ctDNA analysis is
negative, a tissue biopsy may still provide valuable genomic information. In addition,
ctDNA analysis has now been included in numerous clinical trials, shortening the gap
between research and clinical practice.
1.3.3 ctDNA as a biomarker for melanoma
ctDNA as a prognostic biomarker
The potential clinical validity of ctDNA for melanoma management has been addressed
in previous studies. In particular, baseline ctDNA levels have been shown to significantly
correlate with response to therapy [13, 209, 210], and were signiﬁcantly associated with
overall response rate (ORR) and PFS in melanoma patients undergoing targeted therapy
[12, 15, 187, 193]. Ongoing clinical trials show that high basal levels of circulating BRAF
V600E correlated with lower ORR and lower PFS to targeted therapy [12, 15]. These
studies indicate that elevated ctDNA levels are a valid predictor of poor clinical outcome.
Various studies have evaluated the prognostic value of ctDNA in melanoma management.
Baseline ctDNA levels have been shown to significantly correlate with response to
therapy and survival outcomes in melanoma patients receiving targeted therapy [12, 15,
187, 193, 211]. A low baseline ctDNA level has been previously associated with long PFS
in melanoma patients treated with immunotherapies [14, 212] and was found to
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correlate with response to treatment [213-216]. In contrast, Lee et al. showed that a
decline in ctDNA during treatment, but not low baseline levels, predicted longer PFS and
OS [217]. Moreover, decreasing or undetectable ctDNA levels can distinguish between
pseudoprogression or definite disease progression [218].
ctDNA as an indicator of treatment response
Similarly, in melanoma, multiple studies have shown evidence of a signiﬁcant correlation
between ctDNA levels and tumour burden [14, 16, 193]. Since ctDNA is tumour specific
and can expand over a dynamic range, it appears to be a more accurate blood-based
biomarker than the currently used LDH marker for deﬁning patient tumour status [13].
Tsao and colleagues demonstrated that ctDNA levels correlate with tumour burden as
assessed by radiological scans in patients treated with immunotherapies [219].
Furthermore, a close correlation (p<0.001), between ctDNA levels per mL of plasma and
metabolic tumour burden (MTB) (FDG uptake by the tumour assessed by PET/CT [16,
220]) has been identified. Interestingly, PET/CT remains more sensitive than ctDNA
analysis at this stage, since ctDNA was not detectable in patients with an MTB value of
less than 10, defining the limit of detection of ctDNA to date [221]. On the other hand, an
increase in ctDNA levels during or after treatment can indicate disease progression.
Frequent ctDNA analysis may lead to early detection of disease progression [14].
The surveillance of patients after receiving treatment is another potential clinical
application of ctDNA. For patients who have achieved a complete response, ctDNA levels
can be analysed to determine if the cessation of treatment is warranted. Conversely, for
patients that have ceased treatment, monitoring of ctDNA levels, can help identify the
emergence of recurrence.
In regards to early-stage patients, a study in early-stage colorectal cancer involving 230
patients indicated that recurrence-free survival at 3 years was 0% for the patients that
had ctDNA-positive results at first follow-up after surgical resection, and was 90% for
patients with undetectable ctDNA [222]. Similarly, in an early study of 55 breast cancer
patients, ctDNA detection at first follow-up also indicated poor prognosis [223]. Thus, the
detection of ctDNA following surgery or treatment with curative intent may signal the
presence of minimal residual disease (MRD) even in the absence of any other clinical
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evidence of disease. This has not been fully interrogated for melanoma. Further studies
are required to elucidate whether ctDNA detection may indicate the presence of residual
tumour mass that was not eradicated by standard treatment.
ctDNA analysis for comprehensive mutational profile
In melanoma tumours, clonal heterogeneity plays an important role in patient response
to treatment and the development of resistance to treatment. While targeted therapies
can efficiently target dominant clones, they can also drive an increase in the population
of resistant clones. For example, recent studies have shown that ctDNA can be used to
monitor the emergence of mutations responsible for driving acquired resistance to BRAF
and/or MEK inhibitors in melanoma, such as, the NRAS (Q61K), MAP2K1 (E203K), PTEN,
AKT1 [13, 14, 16]. These mutations appear in the ctDNA of patients that developed
acquired resistance to BRAF inhibitor treatments, in some cases earlier than radiological
evidence of disease resistance [224, 225]. In addition, low-coverage WGS and WES
analyses of ctDNA identified BRAF amplification as a potential mechanism of resistance
to MAPK inhibitors [16]. Therefore, monitoring BRAF V600 and NRAS (Q61K/R) ctDNA
levels together with other mutations related to acquired resistance will aid in identifying
when resistance emerges, allowing earlier transition to second-line treatment that leads
to increased response rates and improved patient outcomes [226].
Overall, ctDNA appears to be a clinically valid biomarker with great potential to inform
clinical decisions in melanoma. The ability to reflect tumour burden and clonal evolution
makes it a reliable biomarker for disease monitoring and prediction of response to
treatment. However, important limitations need to be addressed to define the real clinical
utility of ctDNA as a melanoma-specific biomarker.
Firstly, most ctDNA studies thus far have only analysed BRAF or NRAS mutant cases,
which represent approximately 70% of patients. These studies have remarked on the
high fidelity of BRAF mutant ctDNA to reflect disease burden and tumour status of
patients prior to and during treatment [12-14, 210, 227]. However, there is a need to
ascertain the detection rate and kinetics of other common mutations found in melanoma
to determine whether they can be effectively used for patient surveillance during and
post-treatment of BRAF wild-type patients.
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Secondly, the improvement in the clinical management of melanoma and proactive
approach to surveillance by imaging scans means that an increasingly number of patients
are provided BRAF inhibitors and immunotherapy at the early signs of metastatic disease.
Thus, there is now an increase in melanoma patients with low disease burden receiving
therapy. It is therefore imperative to improve the detection rate of ctDNA in melanoma
and to ascertain its utility as a liquid biopsy as a suitable alternative for tissue biopsy for
mutational analysis.
Thirdly, limited studies have evaluated the predictive value of baseline ctDNA in patients
treated with immunotherapy. Hence, studies that clarify the ability of ctDNA to predict
survival in patients treated with immunotherapies are required, particularly examining
prior treatment regimens and mutation status.
Lastly, while previous studies have demonstrated the efficiency of ctDNA to indicate
disease progression earlier than conventional imaging, such comparisons need to be
conducted in a large cohort of patients. Cross-sectional studies aimed at comparing the
efficiency of ctDNA to indicate treatment response or failure and disease progression
against conventional clinical standards will inform whether this liquid biopsy is a suitable
complementary, if not alternative, test for melanoma patient surveillance in the oncology
clinic.
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1.4 Rationale for this study
There is a clear need for novel diagnostic and molecular tools in oncology, particularly in
melanoma. Australia has one of the highest melanoma incidences world-wide and the
annual estimated treatment cost for all new melanoma cases in Australia has risen to
AU$201 million [228]. Numerous health resources are used in melanoma management,
including doctor consultations, tissue biopsies, tumour surgeries, imaging examinations,
targeted treatments, radiation therapies and chemotherapies. Currently, targeted
therapies and immunotherapies are within the standard treatment regimens for
metastatic melanoma in Australia and several other countries [229]. However, these
novel therapies are exceptionally expensive [230, 231] and can have severe side effects.
Therefore, non-invasive and cost-effective biomarkers are required for the early
detection of therapeutic response and disease progression to aid with timely treatment
adjustments.
In recent years, ctDNA has emerged as a clinically relevant oncological biomarker for
tumour genotyping, prognostication and disease monitoring, as demonstrated by the
multiple studies in breast, lung and ovarian cancers [192, 232, 233]. In melanoma, ctDNA
levels before therapy initiation of BRAF inhibitor or immunotherapies, correlated with
tumour burden and were associated with ORR and PFS [12, 15, 187, 193]. Changes in
plasma ctDNA level during treatment was indicative of either response (decreased) or
treatment failure (maintained or increased), even prior to clinically identifiable
progressive disease in some cases [14, 16]. Furthermore, this blood-based biomarker is
isolated from blood using minimally invasive procedures and can be analysed using
relatively low-cost tests, such as ddPCR assays. Thus, ctDNA may provide a holistic, costeffective, and highly specific analysis and tracking of each patient’s disease status for
improved clinical management of melanoma.
Although tumour tissue biopsy remains the gold standard in diagnosis and mutational
analysis for clinical management of melanoma, the acquisition of tumour tissue is often
limited by the need for highly invasive surgical procedures and/or inaccessible tumour
locations. A significant concordance between the mutational profile obtained from tissue
and plasma biopsies has been previously reported [15, 234]. These studies highlight the
ability of ctDNA to capture the genetic heterogeneity of melanoma tumours and its
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potential inclusion in the clinical setting as an alternative to tumour genotyping. It is,
therefore, important to evaluate the clinical validity of ctDNA for the detection of BRAF
V600 mutant patients that will be eligible for BRAF/MEK inhibitor therapy.
The development of new therapies for melanoma has triggered the urgent need to
investigate biomarkers that allow efficient monitoring of patient disease. Baseline ctDNA
levels and subsequent decline with treatment have been indicated as an early predictor
of tumour response and clinical benefit [14, 193, 217]. In melanoma, BRAF mutant ctDNA
is a robust biomarker for disease burden and tumour status of patients before and during
targeted treatment [14, 16, 234, 235]. However, many patients receiving first-line
immunotherapy, especially in Australia, are BRAF WT and may carry NRAS or other
mutations. Therefore, further studies are needed to evaluate the prognostic and
predictive value of early changes in ctDNA levels to inform therapeutic outcomes in BRAF
as well as in non-BRAF metastatic melanoma patients receiving systemic therapies.
Studies have suggested that ctDNA can serve as an indicator of treatment failure prior to
clinically identifiable progressive disease, providing a lead time that may be important
for effective subsequent treatments [14, 16]. However, very few studies [224, 225] have
evaluated the efficacy of ctDNA to identify disease progression in a large cohort of
melanoma patients and compare it to medical imaging, the current gold standard for
disease monitoring.
In conclusion, the overarching aim of this thesis is to evaluate the clinical validity of
ctDNA within specific contexts of use for the management of metastatic melanoma. The
result of these studies provides valuable information to aid the implementation of this
biomarker in the clinic, ultimately improving clinical outcomes of melanoma patients.
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1.4.1 Hypothesis and aims
Hypothesis: Analysis of plasma ctDNA can aid treatment selection, disease monitoring and
surveillance of metastatic melanoma patients.
Aim 1. To determine the detection rate of BRAF mutations in plasma ctDNA and compare
the efficacy of ctDNA as a medium for tumour genotyping relative to current
clinical standards, including a cost analysis.
Aim 2. To evaluate the ability of pre-treatment ctDNA levels to provide prognostic
information in different treatment types and lines of therapies.
Aim 3. To investigate how changes in ctDNA levels early during treatment correlate with
response.
Aim 4. To examine the validity of ctDNA to inform of disease progression in comparison
to conventional clinical imaging.
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4.1 Abstract
We evaluated the predictive value of pre-treatment ctDNA to inform therapeutic
outcomes in metastatic melanoma patients relative to type and line of treatment.
Plasma ctDNA was quantified in 125 samples collected from 110 patients prior to
commencing treatment with immune checkpoint inhibitors (ICI), as first- (N=32) or
second-line (N=27) regimens, or prior to commencing first-line BRAF/MEK inhibitors
therapy (N=66). An external validation cohort included 128 patients commencing ICI
therapies in the first- (N=77) or second-line (N=51) settings.
In the discovery cohort, low ctDNA (≤20 copies/mL) prior to commencing therapy
predicted longer progression-free survival (PFS) in patients treated with first-line ICIs
(Hazard Ratio (HR) 0.20, 95% Confidence Interval (CI) 0.07-0.53, P<0.0001), but not in
the second-line setting. An independent cohort validated that ctDNA is predictive of PFS
in the first-line setting (HR 0.42, 95% CI 0.22-0.83, P=0.006), but not in the second-line
ICI setting. Moreover, ctDNA prior to commencing ICI treatment was not predictive of PFS
for patients pre-treated with BRAF/MEK inhibitors in either the discovery or validation
cohorts. Reduced PFS and overall survival were observed in patients with high ctDNA
receiving anti-PD-1 monotherapy, relative to those treated with combination anti-CTLA4/anti-PD-1 inhibitors.
Pre-treatment ctDNA is a reliable indicator of patient outcome in the first-line ICI
treatment setting but not in the second-line ICI setting, especially in patients pre-treated
with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients
with high ctDNA may preferentially benefit from combined ICI.

Keywords: circulating tumour DNA (ctDNA), melanoma, immunotherapy, immune
checkpoint inhibitors (ICI), progression-free survival, treatment.
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4.2 Introduction
Metastatic melanoma is an aggressive type of skin cancer and responsible for most skin
cancer-related deaths [293, 294]. In the last decade, the emergence of targeted therapy
and immune-checkpoint inhibitor/s (ICI/s) has significantly changed the clinical
management and outcome of melanoma patients [138, 295]. Current treatment options
for unresectable stage III and stage IV disease [296] include BRAF targeted therapies for
patients that have BRAF mutant melanomas, and ICIs with anti-PD-1 alone or in
combination with anti-CTLA-4. However, durable response is only seen in a minority of
patients, and the optimal sequencing of therapies and the selection of the most effective
first-line therapy, remain controversial [297, 298]. The CheckMate 067 trial
demonstrated that the combination ipilimumab and nivolumab resulted in superior longterm survival outcomes compared to either nivolumab or ipilimumab monotherapy, with
a 5-year overall survival of 52% [136]. However, in addition to being a more costly
regimen [299], patients treated with combination therapy experienced more grade 3 or
4 treatment-related adverse events relative to those treated with nivolumab or
ipilimumab alone [299]. Thus, there is a need to better stratify patients who will require
upfront combination therapy from those who may derive a similar benefit from anti-PD1 monotherapy.
The potential clinical utility of ctDNA for melanoma management has been demonstrated
in multiple studies. Elevated baseline ctDNA levels have been shown to significantly
correlate with low overall response rate (ORR) and short progression-free survival (PFS)
in melanoma patients receiving targeted therapy [12, 15, 187, 193]. However, there is a
paucity of studies evaluating the predictive value of baseline ctDNA in patients treated
with immunotherapy. Low baseline ctDNA level has been previously associated with long
PFS in melanoma patients treated with ICI [14] and was found to correlate with tumour
shrinkage on radiology [213]. In contrast, Lee et al. showed that a decline in ctDNA during
treatment, but not low baseline levels, predicted longer PFS and OS [217]. Thus, more
studies are needed to clarify and further refine the predictive value of ctDNA in patients
treated with immunotherapies, particularly taking into consideration the line of therapy,
prior treatment regimens and mutation status.
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In this study, we analysed a prospective cohort of melanoma patients receiving systemic
therapies, including a large proportion of BRAF wild-type (WT) cases. We compared the
predictive value of pre-treatment ctDNA levels to inform survival outcomes in metastatic
melanoma patients receiving first-line or second-line systemic ICI. Our observations were
validated using published datasets from two independent cohort studies [16, 217, 218,
300].

4.3 Materials and methods
4.3.1 Discovery cohort
We analysed a total of 125 baseline plasma samples collected prior to commencing
systemic therapy from 110 patients with unresectable stage IV cutaneous melanoma
enrolled in the study between 2013-2018 at Sir Charles Gairdner Hospital (SCGH) and
Fiona Stanley Hospital (FSH) in Perth, Western Australia. Patients’ characteristics are
presented in Figure 4.1 and Table 4.1. A subset of 15 patients were considered as baseline
for their first- and second-line therapy. This study received approval from the Human
Research Ethics Committee of Edith Cowan University (No. 11543 and No. 18957) and Sir
Charles Gairdner Hospital (No. 2013-246).

Figure 4.1. Study cohorts. Flow charts of the samples included in the analyses, which is
comprised of 125 patients treated with first- or second-line ICI and first-line targeted therapy
from the discovery cohort and 128 validation samples from two independent sites. *Samples
obtained from patients treated with second-line ICI after failing first-line therapy with
BRAF±MEK inhibitors.
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Table 4.1. Clinical characteristics at baseline of the melanoma patients included in the study.
Validation Cohort
Discovery Cohort
st
st
1 line
1 line
2nd line ICI
1st line ICI 2nd line ICI
ICI
TT
N=32 (%)
N=27 (%)
N=66 (%)
N=77 (%)
N=51 (%)
Variable
Age
≤65
>65

12 (38)
20 (62)

14 (52)
13 (48)

41 (62)
25 (38)

38 (49)
39 (51)

30 (59)
21 (41)

Female
Male

7 (22)
25 (78)

7 (26)
20 (74)

24 (36)
42 (64)

25 (32)
52 (68)

20 (39)
31 (61)

4 (13)
6 (19)
14 (43)
8 (25)

7 (26)
1 (3)
11 (41)
8 (30)

14 (21)
6 (9)
30 (46)
16 (24)

1 (1)
16 (21)
18 (23)
13 (17)
29 (38)

2 (4)
1 (2)
9 (18)
17 (33)
22 (43)

2 (6)
30 (94)

5 (19)
22 (81)

2 (3)
64 (97)

1 (1)
76 (99)

8 (16)
43 (84)

8 (25)
6 (19)
18 (56)

10 (37)
9 (33)
8 (30)

29 (44)
19 (29)
18 (27)

55 (71)
19 (25)
3 (4)

35 (69)
16 (31)

22 (69)
10 (31)

1 (3)
17 (64)
9 (33)

8 (10)
29 (38)
15 (20)
25 (32)

13 (25)
26 (51)
8 (16)
4 (8)

Sex

AJCC Stage/M Classification
IIIc
M1a
M1b
M1c
M1d

Brain only metastasis
Yes
No

LDH levels
Normal
Elevated
Not available

Treatment
ICI
Nivolumab
Pembrolizumab
Ipilimumab/Nivolumab
Ipilimumab/Pembrolizumab
Targeted Therapies
Vemurafenib
Dabrafenib
Dabrafenib/Trametinib

4 (6)
1 (2)
61 (92)

Prior lines of therapy
BRAF±MEK inhibitors
Dabrafenib/Trametinib
Encorafenib/Binimetinib
Vemurafenib
ICI
Ipilimumab
Pembrolizumab
Ipilimumab/Nivolumab

19 (70)

34 (67)
1 (2)
1 (2)

6 (22)
2 (8)

14 (27)
1 (2)

BRAF mutation status
BRAF Mutant
2 (6)
21 (78)
NRAS Mutant
17 (53)
1 (3)
BRAF/NRAS WT
13 (41)
5 (19)
TT: targeted therapy, ICI: Immune checkpoint inhibitors.

66 (100)

35 (45)
31 (41)
11 (14)

38 (75)
11 (21)
2 (4)
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Written informed consent was obtained from patients prior to sample collection and
analysis. Patients were clinically monitored, and the median follow-up period was 95
weeks (range: 16-257 weeks).
4.3.2 Validation cohort
We pooled data from two independent cohorts of 128 unresectable stage III (N=3) and
stage IV melanoma (N=125) patients recruited from the Melanoma Institute Australia
(NSW) affiliated hospitals and Peter MacCallum Cancer Centre (Victoria), as previously
described by Lee et al. [217, 218, 300] and Wong et al. [16]. Additional details and patient
characteristics are shown in Figure 4.1 and Table 4.1. Further comparison between the
discovery and validation cohorts is presented in Table S4.1.
4.3.3 Treatment response and disease progression assessment
Radiological assessment of treatment response and disease progression was performed
at two to three monthly intervals by computed tomography (CT) and/or

18F-labeled

fluorodeoxyglucose positron emission tomography (FDG-PET) scans. Magnetic
resonance imaging (MRI) of the brain was also used where indicated. PFS was defined as
the time interval between the start of therapy and the date of first clinical or radiological
progression.
4.3.4 Plasma sample preparation and cfDNA extractions
Pre-treatment blood samples were collected into EDTA vacutainer or Cell-Free DNA
BCT® (Streck, La Vista, NE) tubes. Isolated plasma was stored at -80oC until extraction.
Plasma cfDNA was isolated from 1-5 mL of plasma using QIAmp Circulating Nucleic Acid
Kits (Qiagen, Hilden, Germany), as per the manufacturer’s instructions. The recovered
cfDNA was freezer-stored until ctDNA quantification.
4.3.6 ctDNA quantification
For the discovery cohort, the mutation target for ctDNA analysis was selected based on
the mutation reported in each patient’s molecular pathology result (BRAF mutant) or, if
BRAF WT, obtained from next generation sequencing of tissue biopsy using a custom
melanoma panel, as previously described by Calapre et al. [234]. Commercially available
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and/or customised probes were used to analyse ctDNA by droplet digital PCR (ddPCR).
To cover all patients, we used a total of twenty-two different hotspot sequence variants
in 10 different genes (Table S4.2 and Table S4.3). Droplets were generated using an
Automatic Droplet generator QX200 AutoDG (Bio-Rad) and analysed using the
QuantaSoft analysis software version 1.7.4 (Bio-Rad). Amplifications were performed in
40 µL reactions using previously described cycling conditions [14]. Quantification results
were presented in copies of ctDNA per mL of plasma.
A cutoff of 20 copies/mL was used for comparison of our analyses with the results from
different cohorts analysed in three laboratories. This is the minimum ctDNA
concentration that could be reliably detected given that ctDNA was isolated from 1-5 mL
of plasma, eluted in 30-60 µL, an input of 5-8 µL in the ddPCR reaction and using different
copies per mL of plasma (copies/mL) as threshold based on specific assays (Table S4.2)
[16, 217, 218, 300]. We confirmed the suitability of this cutoff value through ROC curve
analysis using the discovery cohort data for prediction of 6-month PFS (Figure S4.1).
Patients with more than 20 copies/mL were defined as having a high ctDNA level, while
patients ≤20 copies/mL were considered to have low ctDNA level.
4.3.7 Statistics
A comparison of the patients’ characteristics between the discovery and the validation
cohorts was performed using a Chi-Square or two-sided Fisher´s exact test, with the
frequencies, percentages and the P-values reported. Similarly, patient characteristics
were compared by group using a Chi-Square or two-sided Fisher’s exact test, reporting
their corresponding P-values. A ROC curve was calculated to determine the best cutoff
value to dichotomise ctDNA concentration to predict 6-month PFS. Multiple ctDNA cutoffs
were calculated by averaging two consecutive ctDNA values. These values were then used
to calculate survival HRs and 95% CI for each ctDNA cutoff following a previously
described analysis [301].
Median PFS was calculated using the Kaplan-Meier method, and survival curves
statistical significance was determined using the log-rank and Gehan-Breslow-Wilcoxon
test, when indicated, to stress the importance of early events. Univariate and multivariate
Cox regression analyses were performed for PFS and OS comparisons in the discovery
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cohort, the validation cohort and ICI monotherapy or combination cohort. All statistical
analyses were performed using GraphPad Prism version 8 (GraphPad Software Inc.),
SPSS version 25 (IBM) and R Studio (v.1.1.456). Results with P<0.05 were considered
statistically significant.

4.4 Results
4.4.1 Patient characteristics
The discovery cohort comprised of 125 plasma samples. Of these, 66 were from patients
with BRAF mutant melanoma commencing first-line targeted therapy, and most patients
received dabrafenib/trametinib (61/66, 92%; Figure 4.1 and Table 4.1). A total of 32
patients were treated with first-line ICI monotherapy or in combination (22 anti-PD-1
alone, 10 anti-CTLA-4 plus anti-PD-1 combination treatment) and 27 were treated with
second-line ICI/s. Of the latter, 19 (70%) received a combination of BRAF±MEK inhibitors
as first-line treatment, while 8 patients received ICI monotherapy as first line followed
by combination ICI (Table 4.1 and Table S4.1). Overall, the discovery cohort included 2
BRAF mutant patients in the first-line ICI group (2/32, 6%) and 21 in the second-line ICI
group (21/27, 78%).
4.4.2 Baseline ctDNA and progression-free survival
Consistent with previous studies, for patients treated with first-line targeted therapy, low
plasma ctDNA level at baseline was predictive of longer PFS (median: 57 vs 29 weeks, HR
0.54, 95% CI 0.30-0.98, P=0.025; Figure S4.2). We then evaluated the predictive value of
baseline ctDNA levels in patients receiving first- or second-line ICI in the discovery
cohort. No statistically significant differences between clinical patients’ characteristics
were associated with ctDNA levels (Fisher’s exact test, Table S4.4). However, patients
with low ctDNA levels prior to first-line treatment initiation (N=18) had a significantly
longer PFS, with undefined median, compared to patients with high levels of ctDNA
(median PFS 8 weeks, HR 0.20, 95% CI 0.07-0.53, P<0.0001; Figure 4.2A). The predictive
value of ctDNA was significant across multiple cutoff values (Figure S4.3A). Multivariate
Cox regression analysis controlling for age, sex, tumour stage, brain metastases and BRAF
status confirmed that low ctDNA level at baseline was an independent predictor of longer
PFS (HR 5.18, 95% CI 1.88-14.31, P=0.001; Table S4.5).
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Figure 4.2. Kaplan-Meier curves for progression-free survival (PFS) of melanoma patients treated with ICI. Patients were stratified into those with
low (green) or high (red) baseline ctDNA levels. Each graph denotes PFS outcomes in the discovery (A-C) or validation cohorts (D-F); for patients
treated with ICI as first-line (A, D) or second-line treatment (B, E); or for BRAF mutant patients receiving ICI after failing first-line targeted therapy
(C, F). Log-rank P-values, Hazard Ratio (HR) and 95% confidence intervals (CI) are indicated for each plot.
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Analysis of patients receiving ICI as second-line (N=27) failed to demonstrate an
association between low ctDNA and longer PFS (median PFS 31 vs 26 weeks, HR 1.05,
95% CI 0.41-2.72, P=0.913; Figure 4.2B) using 20 copies/mL as cutoff or any other value
(Figure S4.3B). Similar results were observed when removing 5 patients with intracranial
disease only (Figure S4.4A). As 19/27 (70%) of patients receiving second-line ICI, had
BRAF inhibitors (with or without MEK inhibitors) as first-line treatment, we evaluated
the PFS outcome of this sub-group of patients. Low baseline ctDNA in patients
commencing ICI as second-line after failing therapy with BRAF±MEK inhibitors was not
a predictor of longer PFS (median: 30 vs 3 weeks, HR 0.59, 95% CI 0.16-2.24, P=0.356;
Figure 4.2C and Figure S4.3C), contrary to the first-line ICI setting. Nevertheless, this
observation was derived from a small cohort (14 vs. 5) patients.
4.4.3 Validation cohort
Two independent melanoma patient cohorts receiving ICI/s in the first- or second-line
setting were combined and used to validate our findings (N=128). This validation cohort
comprised 77 patients treated with first-line ICI (37 anti-PD-1 monotherapy, 40 antiCTLA-4 plus anti-PD-1 combination) and 51 patients treated with second-line ICI/s. Of
these 51 patients, 36 (71%) were treated with first-line BRAF±MEK inhibitors (Table
S4.1), while 14 (27%) were treated with ipilimumab and 1 (2%) was treated with
ipilimumab plus nivolumab as first-line treatment. The cohort included 35 (35/77, 45%)
BRAF mutant patients in the first-line ICI group and 38 (38/51, 75%) in the second-line
ICI group. The validation cohort had a significantly higher number of BRAF mutant
patients treated with first-line ICI than the discovery cohort (35/77, 45% vs 2/32, 6%,
P<0.0001, respectively; Table S4.1). Similarly, there was a significantly higher number of
patients treated with combination ICIs in the first-line setting than in the discovery
cohort (P=0.048). No other statistical difference in patient characteristics was found
between the validation and the discovery cohorts.
4.4.4 Baseline ctDNA predictive value in the validation cohort
Similar to the discovery cohort, patients with low baseline ctDNA levels prior to first-line
ICI showed a significantly longer PFS than patients with high ctDNA levels (median PFS
undefined vs 42 weeks, HR 0.42, 95% CI 0.22-0.83, P=0.006; Figure 4.2D). The predictive
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value of ctDNA was significant across multiple cutoff values (Figure S4.3D). Multivariate
Cox regression analysis controlling for age, sex, tumour stage, brain metastases, BRAF
status and LDH confirmed that low ctDNA level at baseline prior to first-line ICI, was an
independent predictor for longer PFS (HR 2.423, 95% CI 1.17-5.02, P=0.017; Table S4.6).

Figure 4.3. Kaplan-Meier plots comparing survival of patients receiving first-line single-anti-PD1 and ICI combination. Patients were separated based on high (A-B, red) and low (C-D, green)
baseline ctDNA levels, treated with anti-PD-1 alone (dashed line) or with combination anti-CTLA4 plus anti-PD-1 (solid line). Graphs represent progression-free survival (PFS; A and C) and
overall survival (OS; B and D). Log-rank P-values, Hazard Ratio (HR) and 95% confidence
intervals (CI) are indicated for each plot. *Represents Gehan-Breslow-Wilcoxon P-values.

Similar to the discovery cohort, low ctDNA was not associated with longer PFS in the
second-line setting in the validation cohort (median PFS 49 vs 13 weeks, HR 0.61, 95% CI
0.30-1.25, P=0.143; Figure 4.2E) using 20 copies/mL or below as cutoff value (Figure
S4.3E). Notably, within the group with low ctDNA levels in the second-line ICI setting, a
significantly higher number of patients had metastases in brain-only compared to the
group with high ctDNA levels (P=0.016; Table S4.7). When removing from the analysis
cases with intracranial disease only, patients with high ctDNA levels had decreased PFS
(undefined vs 13 weeks, HR 0.41, 95% CI 0.18-0.93, P=0.023; Figure S4.4B).

93
For BRAF mutant patients who received ICI after failing first-line targeted therapies
(N=36), low baseline ctDNA level did not predict longer PFS in the validation cohort
(median PFS 26 vs 14 weeks, HR 0.92, 95% CI 0.41-2.09, P=0.838; Figure 4.2F and Figure
S4.3F), as observed in the discovery cohort. This result was maintained when removing
from the analysis patients with intracranial disease only (median PFS 26 vs 14 weeks, HR
0.70, 95% CI 0.27-1.78, P=0.431; Figure S4.4C).
4.4.5 Survival analysis in patients with high ctDNA treated with combination or
single agent ICI in the first-line setting
Overall, ctDNA was found to be predictive of PFS in patients treated with first-line ICI.
However, patients with high ctDNA levels in the validation cohort showed longer PFS
compared to patients with similarly high baseline ctDNA levels in the discovery cohort (8
vs 42 weeks, red lines in Figure 4.2A and Figure 4.2D). It is important to note that in the
discovery cohort, only 29% (4/14) of patients with high ctDNA levels at baseline were
treated with combination anti-CTLA-4 plus anti-PD-1 therapy, compared to 58% (19/33)
of patients in the validation cohort (Table S4.4 and Table S4.7).
To investigate whether the combination of ICIs is more effective in patients with high
ctDNA, patients from both cohorts were combined and dichotomised according to
whether they had high or low baseline ctDNA levels. Within these groups, survival
outcomes were compared in patients who received single agent anti-PD-1 versus
combination of ICIs. Comparison of patient characteristics revealed a larger proportion
of BRAF mutant patients with low ctDNA levels received combination therapy (P=0.003;
Table S4.8).
Albeit not significant, a trend showing longer PFS was observed for patients with high
baseline ctDNA treated with combination of ICIs when compared to those who received
anti-PD-1 monotherapy (median: 42 vs 7.5 weeks, HR 1.79, 95% CI 0.90-3.53, P=0.081;
Figure 4.3A). Similarly, patients treated with combination therapy showed longer OS
(median: 186 vs 43 weeks, HR 1.91, 95% CI 0.87-4.21, P=0.104; Figure 4.3B). However,
OS was significant when the Gehan-Breslow-Wilcoxon test was used (P=0.028), reflecting
the difference in events occurring at the beginning of the curve. Patients with low ctDNA
levels showed no differences in PFS or OS when treated with combination of ICIs versus
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monotherapy (HR 1.97, 95% CI 0.87-4.47, P=0.124; Figure 4.3C and HR 1.74, 95%CI 0.634.79, P=0.306; Figure 4.3D, respectively). However, none of the groups reached median
PFS or OS, and a limited number of events were recorded within the follow up time.

4.5 Discussion
Studies investigating the ability of baseline ctDNA to predict treatment outcome in
melanoma patients undergoing ICI are scarce, mainly including BRAF mutant melanomas
and do not differentiate between treatment lines [14, 212, 217]. In this study, we showed
that baseline ctDNA in metastatic melanoma patients receiving first-line ICI is a strong
predictor of clinical outcome, as shown in both the discovery and validation cohorts. In
contrast, the predictive value of ctDNA is lost in second-line ICI, particularly in patients
failing first-line targeted therapy. Overall, our results redefine the context of use of ctDNA
as a predictive biomarker in melanoma patients receiving immunotherapy, confining its
utility to the first-line treatment setting.
Currently, there is paucity of published data related to outcomes of patients who
experience disease progression on BRAF inhibitor therapies and are treated with secondline ICI. A recent retrospective study demonstrated that while ICI first-line efficacy
appears comparable to trial populations, ICI treatment of BRAF mutant patients failing
targeted therapy demonstrated a significantly lower response [302-304], and indeed, any
drug therapy has lower efficacy in the second-line setting [305-307]. Consistent with
these findings, our results demonstrate the limitation of ctDNA as a predictive biomarker
in the second-line setting. Mason et al. found that BRAF mutant patients refractory to firstline targeted therapy have a high proportion of brain metastases (47%) [302], a finding
similar to that observed in the discovery and validation cohorts (37% and 58%,
respectively). The brain is a common site of targeted therapy failure, often contributing
to death [308]. Given that brain metastases have been reported to shed less ctDNA into
the circulation [192, 300], the large proportion of disease progression within the brain,
may contribute to the limited predictive value of ctDNA in this setting. In line with this,
removal of patients with only intracranial metastases from the analysis improved the
ctDNA predictive value in the validation cohort. However, ctDNA still failed to predict PFS
for patients who received prior treatment with targeted therapies.
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The predictive significance of ctDNA levels prior to commencing targeted therapies has
been previously demonstrated, with the absence of detectable ctDNA correlating with
longer survival in large cohorts of melanoma patients [12, 15, 187, 193]. Similarly, we
found that baseline ctDNA level was a strong predictor of clinical outcome in melanoma
patients in the first-line targeted therapy setting, showing that high ctDNA level is
associated with poorer clinical outcomes.
The selection of first-line monotherapy over ICI combination is currently a complex
decision and factors such as median tumour size, LDH levels, BRAF status, presence of
brain metastases and comorbidities must be carefully considered [136, 309, 310]. We
observed that in the validation cohort, more patients with high baseline ctDNA levels
were treated with a combination of ICIs (19/33, 58%), while the patients in our discovery
cohort were mainly treated with single agent ICI (10/14, 71%). In addition, the validation
cohort had a significantly higher proportion of patients treated with a combination of
ipilimumab and pembrolizumab as first-line therapy instead of ipilimumab plus
nivolumab (P=0.006), as part of a clinical trial. Molecular and pre-clinical assessments of
nivolumab and pembrolizumab suggest that these drugs could be interchanged and
differences seen in clinical trials are likely related to patient populations rather than be
drug-dependent [311]. Consequently, we showed that patients with high pre-treatment
ctDNA levels tend to benefit from the combination of anti-CTLA-4 and anti-PD-1 as firstline therapy. Although ctDNA level correlates significantly with tumour burden [16, 235],
multivariate analyses in previous studies have shown ctDNA to be an independent
predictor of survival [217, 235]. In this context, our results suggest that more aggressive
treatment will be particularly beneficial to those patients with high ctDNA levels.
Results from the Checkmate 067 study favours the use of ICI combination over anti-PD-1
monotherapy, showing that patients treated with a combination of ICIs had increased
both response (58% vs 45%) and 5-year overall survival rates (52% vs 44%) compared
with those treated with anti-PD-1 monotherapy. These differences were accentuated in
patients with BRAF mutations, with an increased 5-year survival rate in the combination
group (60% vs 46%) [136]. In addition, it has been described that in patients with PD-L1
negative tumours, the combination of PD-1 and CTLA-4 blockade was more effective than
was either agent alone [109, 136]. Based on our results, elevated ctDNA may identify a
group of melanoma patients that could benefit from ICI combination treatment. However,
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our study was limited by the low number of patients with high ctDNA included in the
survival analysis of single agent anti-PD-1 and combination of ICIs. Further prospective
clinical trials are needed to confirm our observations and validate the use of ctDNA as a
predictive biomarker for the treatment of melanoma patients.
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4.8 Supplementary Material
Table S4.1. Comparison of the patients’ characteristics between the discovery cohort (N=59) and the validation cohort (N=128).
Variable
Age
≤65
>65
Sex
Female
Male
AJCC Stage/M Classification
IIIc/M1a/M1b
M1c/M1d
Brain metastasis
Yes
No
Brain only metastasis
Yes
No
LDH levels
Normal
Elevated
N/A
Treatment
Nivolumab
Pembrolizumab
Ipilimumab/Nivolumab
Ipilimumab/Pembrolizumab
First-line therapy
Vemurafenib
Encorafenib/Binimetinib
Dabrafenib/Trametinib
Ipilimumab
Pembrolizumab
Ipilimumab/Nivolumab
BRAF mutation status
BRAF V600 Mutant
BRAF V600 WT

Discovery
N=32 (%)

First-line ICI
Validation
Total
N=77 (%)
N=109 (%)

P-value

Discovery
N=27 (%)

Second-line ICI
Validation
Total
N=51 (%)
N=78 (%)

P-value

ICI after Targeted Therapy
Discovery Validation
Total
N=19 (%)
N=36 (%)
N=55 (%)

P-value

12 (38)
20 (62)

38 (49)
39 (51)

50 (46)
59 (54)

0.296

14 (52)
13 (48)

30 (59)
21 (41)

44 (56)
34 (44)

0.634

8 (42)
11 (58)

21 (58)
15 (42)

29 (53)
26 (47)

0.273

7 (22)
25 (78)

25 (32)
52 (68)

32 (29)
77 (71)

0.357

7 (26)
20 (74)

20 (39)
31 (61)

27 (35)
51 (65)

0.319

5 (26)
14 (74)

15 (42)
21 (58)

20 (36)
35 (64)

0.378

10 (32)
22 (68)

35 (45)
42 (55)

45 (41)
64 (59)

0.203

8 (30)
19 (70)

12 (24)
39 (76)

20 (26)
58 (74)

0.593

6 (32)
13 (68)

7 (19)
29 (81)

13 (24)
42 (76)

0.336

8 (25)
24 (75)

29 (38)
48 (62)

37 (34)
72 (66)

0.268

8 (30)
19 (70)

22 (43)
29 (57)

30 (38)
48 (62)

0.758

7 (37)
12 (63)

21 (58)
15 (42)

28 (51)
27 (49)

0.163

2 (6)
30 (94)

1 (1)
76 (99)

3 (3)
106 (97)

0.206

5 (19)
22 (81)

8 (16)
43 (84)

13 (17)
65 (83)

0.758

5 (26)
14 (74)

8 (22)
28 (78)

13 (24)
42 (76)

0.749

8 (25)
6 (19)
18 (56)

55 (71)
19 (25)
3 (4)

63 (58)
25 (23)
21 (19)

-

10 (37)
9 (33)
8 (30)

35 (69)
16 (31)

45 (58)
25 (32)
8 (10)

6 (32)
6 (32)
7 (34)

24 (67)
12 (33)

30 (54)
18 (33)
7 (13)

-

22 (69)
10 (31)

8 (10)
29 (38)
15 (20)
25 (32)

8 (7)
51 (47)
25 (23)
25 (23)

1 (3)
17 (64)
9 (33)

13 (25)
26 (51)
8 (16)
4 (8)

14 (18)
43 (55)
17 (22)
4 (5)

8 (22)
16 (44)
5 (14)
7 (20)

8 (14)
28 (51)
12 (22)
7 (13)

*0.999

1 (2)
1 (2)
34 (67)
14 (27)

19 (100)

1 (2)
1 (2)
53 (96)

-

-

1 (3)
1 (3)
34 (94)

1 (2)

1 (1)
1 (1)
53 (68)
20 (26)
2 (3)
1 (1)

38 (75)
13 (25)

59 (76)
19 (24)

0.656

19 (100)

36 (100)

55 (100)

*0.048

19 (70)
6 (22)
2 (8)

2 (6)
30 (94)

35 (45)
42 (55)

37 (34)
72 (66)

<0.0001

21 (78)
6 (22)

-

*0.424

12 (63)
7 (37)

*Analysis performed comparing anti-PD-1 monotherapy and anti-CTLA-4 plus anti-PD-1 combination therapy. N/A – not available.

-
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Table S4.2. Specificity of ddPCR assays.
Healthy controls
Assay
Positive Negative

Maximum false positive
concentration (copies/mL)

BRAF V600E

0

22

0

BRAF V600K
BRAF V600R
BRAF V600E2
BRAF K601E
BRAF L597Q
NRAS Q61K
NRAS Q61L
NRAS Q61R
NRAS G12D
NRAS G13D
TERT C228T/C250T Mult.
DPH3 C8T
GRM3 E538K
GRM3 S491L
FLT1 E011K
KIT L576P
NF1 P1851S
RAC1 P29S
TP53 R248W
TP53 R248Q
TP53 R158H

0
0
1
3
0
0
3
7
4
4
6
1
0
6
3
1
3
0
2
6
1

23
24
12
7
16
19
9
24
6
6
50
10
10
12
7
11
11
12
14
8
9

0
0
1
2
0
0
7
9
3
5
10
2
0
6
9
2
3
0
2
2
2

Company
Life
Technologies
IDT
IDT
IDT
IDT
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
IDT
IDT
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
Bio-Rad
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Table S4.3. Mutation status of the melanoma patients included in the study.
Validation Cohort
Discovery Cohort
2nd line
1st line ICI 2nd line ICI 1st line TT
1st line ICI
ICI
N=32 (%)
N=27 (%)
N=66 (%)
N=77 (%)
N=51 (%)
Mutation status
BRAF
BRAF V600E
BRAF V600E2
BRAF V600K
BRAF V600R
BRAF K601E
BRAF L597Q
BRAF L597S
BRAF L597R
BRAF G466E
NRAS
NRAS Q61K
NRAS Q61L
NRAS Q61R
NRAS Q61H
NRAS G12D
NRAS G13D
TERT
TERT Mult.
TERT C228T
TERT C250T
TERT -125CC>TT
GRM3
GRM3 E538K
GRM3 S491L
FLT1
FLT1 E1011K
KIT
KIT L576P
KIT K642E
NF1
NF1 P185S
RAC1
RAC1 P29S
TP53
TP53 R158H
TP53 R248W
TP53 R248Q
TP53 Y220S
DPH3
DPH3 C8T

13 (48)

1 (3)
1 (3)
1 (3)

5 (18)
2 (6)
1 (4)

50 (76)
1 (2)
12 (18)
3 (4)

24 (31)

27 (53)

11 (14)

9 (17)
2 (4)

1 (1)
1 (2)
2 (3)
1 (1)

8 (25)
4 (13)
3 (9)

1 (4)

12 (16)
5 (7)
13 (18)
1 (1)

4 (8)
2 (4)
4 (8)
1 (2)

1 (3)
1 (3)
1 (3)
1 (3)
1 (3)

1 (4)
1 (4)
1 (2)

1 (3)
1 (3)
1 (3)
2 (7)

1 (1)
4 (5)
1 (4)

2 (7)

1 (1)

1 (3)
1 (3)
1 (4)
1 (1)
1 (4)
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Table S4.4. Clinical characteristics at baseline of the melanoma patients included in the survival analysis of the discovery cohort.
Variable
Age
≤65
>65
Sex
Female
Male
Melanoma Subtype
Cutaneous
AJCC Stage/M Classification
M1a/M1b
M1c/M1d
ECOG
0
1-3
Brain metastasis
Yes
No
Brain only metastasis
Yes
No
LDH levels
Normal
Elevated
N/A
Therapy
Nivolumab
Pembrolizumab
Ipilimumab/Nivolumab
Timing of blood draw
During 1st line Rx
After 1st line Rx
BRAF mutation status
BRAF V600 Mutant
BRAF V600 WT

Low ctDNA
N=18 (%)

First-line ICI
High ctDNA
N=14 (%)

Total
N=32 (%)

5 (28)
13 (72)

7 (50)
7 (50)

12 (38)
20 (62)

0.277

9 (50)
9 (50)

5 (56)
4 (44)

14 (52)
13 (48)

0.999

5 (36)
9 (64)

3 (60)
2 (40)

8 (42)
11 (58)

0.603

3 (17)
15 (83)

4 (29)
10 (71)

7 (22)
25 (78)

0.669

6 (33)
12 (67)

1 (12)
8 (88)

7 (26)
20 (74)

0.363

4 (29)
10 (71)

1 (20)
4 (80)

5 (26)
14 (74)

0.999

18 (100)

14 (100)

32 (100)

-

18 (100)

9 (100)

27 (100)

-

14 (100)

5 (100)

19 (100)

-

8 (44)
10 (56)

2 (14)
12 (86)

10 (32)
22 (68)

0.124

6 (33)
12 (67)

2 (24)
7 (76)

8 (30)
19 (70)

0.676

5 (36)
9 (64)

1 (20)
4 (80)

6 (32)
13 (68)

0.999

11 (61)
7 (39)

4 (29)
10 (71)

15 (46)
17 (54)

0.087

11 (61)
7 (39)

3 (33)
6 (67)

14 (52)
13 (48)

0.237

8 (57)
6 (43)

2 (40)
3 (60)

10 (53)
9 (47)

0.629

5 (28)
13 (72)

3 (21)
11 (79)

8 (25)
24 (75)

0.999

6 (33)
12 (67)

2 (24)
7 (76)

8 (30)
19 (70)

0.676

6 (43)
8 (57)

1 (20)
4 (80)

7 (37)
12 (63)

0.603

2 (11)
16 (89)

14 (100)

2 (6)
30 (94)

0.492

5 (28)
13 (72)

9 (100)

5 (19)
22 (81)

0.136

5 (36)
9 (64)

5 (100)

5 (26)
14 (74)

0.257

6 (33)
1 (6)
11 (61)

2 (14)
5 (36)
7 (50)

8 (25)
6 (19)
18 (56)

10 (55)
3 (17)
5 (28)

6 (67)
3 (33)

10 (37)
9 (33)
8 (30)

6 (43)
3 (21)
5 (36)

3 (60)
2 (40)

6 (32)
6 (32)
7 (34)

12 (67)
6 (33)

10 (71)
4 (29)

22 (69)
10 (31)

1 (6)
9 (50)
8 (44)

8 (89)
1 (11)

1 (3)
17 (64)
9 (33)

1 (6)
17 (94)

1 (7)
13 (93)

2 (6)
30 (94)

P-value

-

0.999

0.999

Low ctDNA
N=18 (%)

15 (83)
3 (17)

Second-line ICI
High ctDNA
N=9 (%)

6 (67)
3 (33)

Total
N=27 (%)

21 (78)
6 (22)

P-value

-

*0.193

0.367

ICI after Targeted Therapy
Low ctDNA High ctDNA
Total
N=14 (%)
N=5 (%)
N=19 (%)

P-value

-

7 (50)
7 (50)

5 (100)

12 (63)
7 (37)

0.106

8 (57)
6 (43)

2 (40)
3 (60)

10 (53)
9 (47)

0.629

14 (100)

5 (100)

19 (100)

*Analysis performed comparing anti-PD-1 monotherapy and anti-CTLA-4 plus anti-PD-1 combination therapy. N/A – not available.

-
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Table S4.5. Multivariate Cox proportional-hazards regression analysis for associations between
ctDNA levels and PFS in patients receiving first-line ICI in the discovery cohort (N=32).
First-line ICIs
Univariate
Variables

Multivariate

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (≤65 vs. >65)

0.84 (0.34 - 2.09)

0.705

1.06 (0.39 - 2.85)

0.906

Sex (female vs. male)

0.54 (0.20 - 1.42)

0.209

0.65 (0.23 - 1.81)

0.405

AJCC Stage (M1a/b vs. M1c/d)

4.05 (1.17 - 14.02) 0.027

Brain metastasis (no vs. yes)

2.31 (0.89 - 5.92)

0.082

2.59 (0.67 - 10.12) 0.170
1.84 (0.61 - 5.58)

0.283

BRAF mutation status (mut vs. WT) 1.33 (0.18 - 10.02) 0.779

1.23 (0.14 - 10.47) 0.851

ctDNA levels (low vs. high)

5.18 (1.88 - 14.31) 0.001

5.70 (2.11 - 15.38) <0.001

Table S4.6. Multivariate Cox proportional-hazards regression analysis for associations between
ctDNA levels and PFS in patients receiving first-line ICIs in the validation cohort (N=77).
First-line ICI
Univariate
Variables

Multivariate

HR (95% CI)

P-value

Age (≤65 vs. >65)

1.08 (0.57 - 2.03)

0.824

0.72 (0.33 - 1.59) 0.419

Sex (female vs. male)

1.27 (0.63 - 2.55)

0.512

1.28 (0.58 - 2.81)

0.545

AJCC Stage (IIIc/M1a/b vs. M1c/d)

1.44 (0.75 - 2.76)

0.272

1.58 (0.62 - 3.03)

0.341

LDH levels (normal vs. elevated)

1.13 (0.53 – 2.41) 0.752

0.74 (0.32 – 1.71) 0.484

Brain metastasis (no vs. yes)

1.24 (0.65 - 2.38)

0.514

0.94 (0.38 - 2.32)

0.889

BRAF mutation status (mut vs. WT) 1.33 (0.69 - 2.54)

0.397

1.52 (0.72 - 3.23)

0.273

ctDNA levels (low vs. high)

0.008

2.42 (1.17 - 5.02)

0.017

2.39 (1.26 - 4.55)

HR (95% CI)

P-value
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Table S4.7. Clinical characteristics at baseline of the melanoma patients included in the survival analysis of the validation cohort.
Variable
Age
≤65
>65
Sex
Female
Male
Melanoma Subtype
Cutaneous
Acral
Mucosal
N/A
AJCC Stage/M Classification
IIIc/M1a/M1b
M1c/M1d
ECOG
0
1-3
N/A
Brain metastasis
Yes
No
Brain only metastasis
Yes
No
LDH levels
Normal
Elevated
N/A
Therapy
Nivolumab
Pembrolizumab
Ipilimumab/Nivolumab
Ipilimumab/Pembrolizumab
Timing of blood draw
During 1st line Rx
After 1st line Rx
BRAF mutation status
BRAF V600 Mutant
BRAF V600 WT

Low ctDNA
N=44 (%)

First-line ICI
High ctDNA
N=33 (%)

Total
N=77 (%)

23 (51)
21 (49)

15 (45)
18 (55)

38 (49)
39 (51)

0.647

18 (58)
13 (42)

12 (60)
8 (40)

30 (59)
21 (41)

0.999

14 (61)
9 (39)

7 (54)
6 (46)

21 (58)
15 (42)

0.736

16 (36)
28 (64)

9 (27)
24 (73)

25 (32)
52 (68)

0.466

11 (35)
20 (65)

9 (45)
11 (55)

20 (39)
31 (61)

0.565

8 (35)
15 (65)

7 (54)
6 (46)

15 (42)
21 (58)

0.310

33 (76)
1 (2)
1 (2)
9 (20)

27 (82)
1 (3)

-

26 (84)
1 (3)

12 (60)
2 (10)

38 (75)
3 (6)

19 (82)
1 (5)

8 (62)
1 (7)

27 (74)
2 (6)

5 (15)

60 (78)
2 (3)
1 (1)
14 (18)

4 (13)

6 (30)

10 (19)

3 (13)

4 (31)

7 (20)

24 (55)
20 (45)

11 (33)
22 (67)

35 (45)
42 (55)

0.071

8 (26)
23 (74)

4 (20)
16 (80)

12 (24)
39 (76)

5 (22)
18 (78)

2 (15)
11 (85)

7 (19)
29 (81)

26 (59)
11 (25)
7 (16)

16 (48)
14 (42)
3 (10)

42 (55)
25 (32)
10 (13)

16 (52)
9 (29)
6 (19)

4 (20)
10 (50)
6 (30)

20 (39)
19 (37)
12 (24)

10 (43)
8 (35)
5 (22)

1 (7)
7 (54)
5 (39)

11 (30)
15 (42)
10 (28)

13 (30)
31 (70)

16 (48)
17 (52)

29 (38)
48 (62)

0.102

16 (52)
15 (48)

6 (30)
14 (70)

22 (43)
29 (57)

0.157

16 (70)
7 (30)

5 (38)
8 (62)

21 (58)
15 (42)

0.089

1 (2)
43 (98)

33 (100)

1 (1)
76 (99)

0.999

8 (26)
23 (74)

20 (100)

8 (16)
43 (84)

0.016

8 (35)
15 (65)

13 (100)

8 (22)
28 (78)

0.032

38 (86)
5 (11)
1 (3)

17 (52)
14 (42)
2 (6)

55 (71)
19 (25)
3 (4)

0.002

24 (77)
7 (23)

11 (55)
9 (45)

35 (69)
16 (31)

0.126

18 (78)
5 (22)

6 (46)
7 (54)

24 (67)
12 (33)

0.071

3 (7)
20 (45)
6 (14)
15 (34)

5 (15)
9 (27)
9 (27)
10 (31)

8 (10)
29 (38)
15 (20)
25 (32)

*0.491

11 (35)
13 (42)
4 (13)
3 (10)

2 (10)
13 (65)
4 (20)
1 (5)

13 (25)
26 (51)
8 (16)
4 (8)

*0.999

7 (30)
9 (39)
4 (17)
3 (13)

1 (7)
7 (55)
1 (7)
4 (31)

8 (22)
16 (44)
5 (14)
7 (20)

*0.720

6 (26)
17 (74)

3 (23)
10 (77)

9 (25)
27 (75)

0.999

23 (100)

13 (100)

36 (100)

20 (45)
24 (55)

15 (45)
18 (55)

35 (45)
42 (55)

P-value

-

0.999

Low ctDNA
N=31 (%)

24 (77)
7 (23)

Second-line ICI
High ctDNA
N=20 (%)

14 (70)
6 (30)

Total
N=51 (%)

38 (75)
13 (25)

P-value

-

0.743

-

0.743

ICI after Targeted Therapy
Low ctDNA High ctDNA
Total
N=23 (%)
N=13 (%)
N=36 (%)

*Analysis performed comparing anti-PD-1 monotherapy and anti-CTLA-4 plus anti-PD-1 combination therapy. N/A – not available.

P-value

-

0.999

-

-
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Table S4.8. Clinical characteristics at baseline of the melanoma patients included in Figure 4.3.

Variable
Age
≤65
>65
Sex
Female
Male
AJCC Stage/M Classification
IIIc/M1a/M1b
M1c/M1d
Brain metastasis
Yes
No
Brain only metastasis
Yes
No
LDH levels
Normal
Elevated
N/A
BRAF mutation status
BRAF V600 Mutant
BRAF V600 WT

High ctDNA
Combination
Anti-PD-1
Immunotherapy monotherapy
N=23 (%)
N=24 (%)

Total

P-value

N=47 (%)

Low ctDNA
Combination
Anti-PD-1
Immunotherapy
monotherapy
N=27 (%)
N=35 (%)

Total

P-value

N=62 (%)

10 (43)
13 (57)

9 (37.5)
15 (62.5)

19 (40)
28 (60)

0.770

16 (59)
11 (41)

12 (34)
23 (66)

28 (45)
34 (55)

0.721

9 (39)
14 (61)

4 (17)
20 (83)

13 (28)
34 (72)

0.110

11 (41)
16 (59)

8 (23)
27 (77)

19 (31)
43 (69)

0.169

7 (30)
16 (70)

6 (25)
18 (75)

13 (28)
34 (72)

0.751

13 (48)
14 (52)

19 (54)
16 (46)

32 (52)
30 (48)

0.798

10 (43)
13 (57)

9 (37.5)
15 (62.5)

19 (40)
28 (60)

0.770

10 (37)
17 (63)

8 (23)
27 (77)

18 (29)
44 (71)

0.267

23 (100)

24 (100)

47 (100)

-

2 (7)
25 (93)

1 (3)
34 (97)

3 (5)
59 (95)

0.575

10 (43)
12 (52)
1 (5)

9 (38)
7 (29)
8 (33)

19 (40)
19 (40)
9 (20)

-

20 (74)
4 (15)
3 (11)

24 (69)
2 (5)
9 (26)

44 (71)
6 (10)
12 (19)

-

11 (48)
12 (52)

5 (21)
19 (79)

16 (34)
31 (66)

0.068

15 (56)
12 (44)

6 (17)
29 (83)

21 (34)
41 (66)

0.003
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Figure S4.1. ROC curve for ctDNA values in the first-line ICI for the discovery cohort. Analysis was performed using 6 months PFS as read out. The
table indicates the sensitivity and the specificity associated to each cuttoff value. Highlighted in yellow and indicated by the arrow is the cuttoff values
surrounding 20 copies per mL. Data was analysed and plotted using SPSS.
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100
80

Baseline ctDNA

Median
PFS

No. of
events

Low ctDNA levels (N=37)

57 wks

26

High ctDNA levels (N=29)

29 wks

21

HR 0.54, 95% CI 0.30-0.98, P=0.025
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Figure S4.2. Baseline ctDNA levels relative to survival in first-line targeted therapy. Progressionfree survival (PFS) curve of melanoma patients with low and high ctDNA levels in the study
cohort. Significant Cox regression P-values, Hazard Ratio (HR) and 95% confidence intervals (CI)
are indicated in the plot.
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Figure S4.3. Cutoff optimisation by correlation with survival and ctDNA data. A-F, Relation between various ctDNA cutoffs, progression-free survival
(PFS) and hazard ratio (HR) value, including 95% CI (grey shade). Each dot represents a possible ctDNA cutoff, and red dots denote non-predictive
cutoffs (P>0.05), in the discovery (A-C) or validation cohorts (D-F). Each graph denotes survival HR for ctDNA cutoffs in patients treated with firstline ICI baselines (A, D), second-line ICI baselines (B, E) or only BRAF mutant patients receiving ICI that were treated with first-line targeted therapy
(C, F).
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Figure S4.4. Kaplan-Meier curves for progression-free survival (PFS) of second-line melanoma patients without intracranial disease only treated with
ICI. Patients were stratified into those with low (green) or high (red) baseline ctDNA levels. Each graph denotes PFS outcomes in the discovery (A) or
validation cohorts (B, C); for patients treated with ICI as second-line treatment (A, B); or for BRAF mutant patients receiving ICI after failing first-line
targeted therapy (C). Log-rank P-values, Hazard Ratio (HR) and 95% confidence intervals (CI) are indicated for each plot.

108

CHAPTER 5. THE PROGNOSTIC IMPACT OF CIRCULATING
TUMOUR DNA IN MELANOMA PATIENTS TREATED WITH
SYSTEMIC THERAPIES: BEYOND BRAF MUTANT DETECTION
Publication details
This chapter is a manuscript which has been published in a peer-reviewed journal and it
is aimed at a general clinical audience. Cancers, 2020.

Authors
Gabriela Marsavela1, Peter A. Johansson2, Michelle R. Pereira1, Ashleigh C. McEvoy1, Anna
L. Reid1, Cleo Robinson3,4, Lydia Warburton1,5, Muhammad A. Khattak1,6,7, Tarek M.
Meniawy1,5,6, Benhur Amanuel1,3,6, Michael Millward5,6, Nicholas K. Hayward2, Melanie R.
Ziman1,4, Elin S. Gray1, and Leslie Calapre1.
1School

of Medical and Health Sciences, Edith Cowan University, Western Australia. 2 QIMR

Berghofer Medical Research Institute, Herston, Brisbane, QLD, Australia. 3Anatomical
Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, Western
Australia, Australia. 4School of Biomedical Sciences, University of Western Australia,
Crawley, Western Australia, Australia. 5Department of Medical Oncology, Sir Charles
Gairdner Hospital, Nedlands, Western Australia, Australia. 6School of Medicine, University
of Western Australia, Crawley, Western Australia, Australia. 7Department of Medical
Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

109

5.1 Abstract
In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to
inform therapeutic outcomes in metastatic melanoma patients receiving systemic
therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to
commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72
with immunotherapies. Patient specific droplet digital polymerase chain reaction assays
were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior
to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the
immunotherapy cohort was comparably lower than those with BRAF inhibitors (76%,
P=0.0149). Decreasing ctDNA levels within 12 weeks of treatment was strongly
concordant with treatment response (Cohen’s k=0.798, P<0.001) and predictive of longer
progression free survival. Notably, a slower kinetic of ctDNA decline was observed in
patients treated with immunotherapy compared to those on BRAF/MEK inhibitors.
Whole exome sequencing of ctDNA was also conducted in 9 patients commencing antiPD-1 therapy to derive tumour mutational burden (TMB) and neoepitope load
measurements. The results showed a trend of high TMB and neoepitope load in
responders compared to non-responders. Overall, our data suggest that changes in ctDNA
can serve as an early indicator of therapy outcomes in metastatic melanoma patients
treated with systemic therapies and therefore may serve as a tool to guide treatment
decisions.

Keywords: circulating tumour DNA (ctDNA), melanoma, BRAF, response, targeted
therapy, immunotherapy, neoantigen load, tumour mutational burden.
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5.2 Introduction
In recent years, improved knowledge of melanoma pathogenesis has led to the
development of BRAF and MEK inhibitors that target tumours carrying BRAF oncogenic
mutations, accounting for 40%-50% of all melanoma cases. Similarly, antibody-mediated
blockade of immune checkpoints, particularly the cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4) and the programmed cell-death protein 1 (PD-1), have markedly
improved patient outcome in the last 5 years [116, 129, 152, 226, 312, 313]. However, a
significant number of patients do not achieve sustained benefit from either targeted
therapy or immunotherapy [129, 152, 226, 312, 313]. The most appropriate treatment
sequence or therapy combinations that can maximise patient outcomes remains
controversial [297, 314]. Predictive biomarkers of therapy response that can be assessed
prior to initiation of treatment and early during therapy are critical to guide clinical
management of metastatic melanoma.
Analysis of tumour specific cell-free DNA (cfDNA) has been previously reported to be a
reliable companion diagnostic biomarker in oncology [192, 275, 315, 316]. In melanoma,
circulating tumour DNA (ctDNA) is a potential non-invasive alternative to tumour tissue
biopsy for molecular profiling and longitudinal disease monitoring in the metastatic
setting [317]. In addition, baseline ctDNA levels and subsequent decline with treatment
have been indicated as an early predictor of tumour response and clinical benefit [14,
193, 217]. To confirm the utility of ctDNA as a clinical biomarker, its ability to monitor
and/or predict treatment response and clinical outcome requires further validation in a
large cohort of melanoma patients, especially in those treated with immunotherapy.
In melanoma, BRAF mutant ctDNA has been found to be a robust biomarker for disease
burden and tumour status of patients prior to and during targeted treatment [14, 16, 234,
235]. However, many patients receiving immunotherapy, are BRAF wild-type (WT). Thus,
the detection rate of ctDNA and the value of ctDNA-based longitudinal monitoring in nonBRAF melanoma patients need to be specifically assessed.
Mutations, genetic rearrangements, insertions and deletions can encode novel, cancerspecific neoantigens. Activation of T-cells is initiated by the recognition of novel peptides
presented by human leukocyte antigens (HLA) complex. A high tumour mutational
burden (TMB) was associated with better survival outcomes in non-small cell lung
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cancer (NSCLC) [318-322], melanoma [323, 324] and other cancers. Nonetheless, the
predictive value of tissue-derived TMB for immunotherapy response needs further
scrutiny and standardisation [325-327]. In this context, ctDNA has the potential to
capture the mutational profile of all existing metastases [16]. However, whether this
biomarker presents as an easily accessible and suitable tumour source for whole exome
mutational load analysis and TMB measurement or neoepitope predictions in melanoma
needs to be further defined.
In this study, we aimed to ascertain the clinical utility of ctDNA to inform treatment
response and survival in metastatic melanoma patients receiving systemic therapy. We
compared ctDNA levels, detection rates, decay kinetics and predictive value between
patients treated with immune checkpoint inhibitors and targeted therapies. We also
explored whether ctDNA can be used for estimating tumour mutational and neoepitope
load, to predict response to immune checkpoint inhibiting therapies.

5.3 Materials and methods
5.3.1 Patients
We analysed a total of 142 plasma samples collected prior to commencing systemic
therapy and 227 follow-up samples collected within 24 weeks of treatment initiation
from 118 metastatic melanoma patients enrolled in the study between 2013-2018 at Sir
Charles Gairdner Hospital (SCGH) and Fiona Stanley Hospital (FSH) in Perth, Western
Australia. A subset of 24 patients were considered as baseline for their first- and secondline therapy. Additional details of study design and patient inclusion or exclusion criteria
in the different analyses can be found in Fig. S2. Approval by the Human Research Ethics
Committee protocols from Edith Cowan University (No. 11543 and No. 18957) and Sir
Charles Gairdner Hospital (No. 2013-246) was granted for this prospective study. Written
informed consent was obtained from each subject prior to sample collection and analysis.
Experiments were performed in accordance with institutional and national guidelines
and regulations. Patients were clinically monitored with median follow-up duration of
113 weeks (range: 28-286 weeks). Patient characteristics and clinical parameters are
summarised in Table S5.4.
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5.3.2 Treatment response and disease progression assessment
Tumour disease responses were assessed radiologically by computed tomography (CT)
and/or 18F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) scans
at two to three monthly intervals. Patients were defined as responders if they had
significant reduction in tumour size by the RECIST 1.1 on CT or FDG-PET scan as per the
treating clinician, or presented a durable stable disease lasting more than 6 months.
Progression-free survival (PFS) was defined as the time interval between the start of
therapy and the date of first clinical progression. Overall survival (OS) was defined as the
time interval between the start of therapy and death. Additionally, metastatic melanoma
patients were stratified into four M-subcategories at baseline based on the location of the
metastases [296].
5.3.3 Plasma samples preparation and cfDNA extractions
Blood samples were collected prior to initiation of treatment and during subsequent
follow-ups, into EDTA vacutainer or Cell-Free DNA BCT® (Streck, La Vista, NE) tubes.
Within 24 hours of blood collection, plasma was separated by centrifugation at 300 g for
20 minutes, followed by a second centrifugation at 4700 g for 10 minutes. All isolated
plasma was stored at -80oC until extraction. Plasma cfDNA was isolated from 1-5 mL of
plasma using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) as per the
manufacturer’s instructions. The recovered cfDNA was eluted in 40 µL AVE buffer
(Qiagen, Hilden, Germany) and stored at -80oC until ctDNA quantification by droplet
digital PCR (ddPCR).
5.3.4 Tissue analysis
Mutational profile of BRAF WT patients were identified from tissue biopsies as previously
described by Calapre et al. [234] A custom targeted next generation sequencing panel of
30 melanoma-associated genes (Illumina, San Diego, CA, USA) with 950 amplicons and an
Illumina MiSeq instrument were used to identify mutational targets for ctDNA analysis in
BRAF WT patients. Genomic variants were annotated using the Illumina Variant Studio
3.0 software (Illumina). Mutational targets were selected based on the criteria previously
described [234].
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5.3.5 Plasma ctDNA analysis
Commercially available and/or customised probes were used to analyse ctDNA by ddPCR.
Droplets were generated using an Automatic Droplet generator QX200 AutoDG (Bio-Rad,
Hercules, CA). Amplifications were performed in 40µL reactions using cycling conditions
previously described [14]. Twenty-six different mutation variants in 10 different genes
were utilised. Customised primers and probes for TERT and DPH3 promoter mutation
analyses were performed as previously reported by McEvoy et al. [257] and Calapre et al.
[234], respectively. Limit of blank for the ctDNA assays was determined using normal
plasma samples from at least 10 healthy controls. Levels of ctDNA were defined based on
the level of false positive droplets as previously specified in Calapre et al. [234] or are
detailed in Table S5.5. Samples yielding copies/mL of plasma equal or below the
maximum false positive concentration were deemed ctDNA negative.
5.3.6 Whole exome sequencing
The concentrations of cfDNA used for WES ranged from 1 to 7 ng/uL of cfDNA, with ctDNA
fraction >7% abundance. Whole exome sequencing (WES) was carried out using the
Exome-seq Agilent V6 capture Kit (Agilent) by Novogene (Hong Kong, China). Sequence
reads were aligned against human reference genome (hg19) using the Burrows-Wheeler
aligner (BWA). Duplicate reads were marked with Picard Tools, reads were realigned
against known indels and base qualities recalibrated using Genome Analysis Toolkit. As
BWA assumes a unimodal distribution of fragment size, we adjusted the Proper Pair bit
in read pairs following the approach in BWA but the fragment sizes were fitted against a
mixture of two Gaussian models.
Somatic variants were identified with an in-house tool using the statistical framework
described by Li et al. [328] We used a model assuming diploid germline and calculated
the phred-scaled likelihoods for possible genotypes. The tumour sample was modelled as
a mixture of tumour and normal cell DNA and likelihoods were calculated for an array of
different variant allele frequencies. The constrained log-likelihood ratio (CLR) was
calculated and variants with CLR score of <70 were excluded from further analysis.
Identified variants were further annotated using ANNOVAR.

114
5.3.7 Neoepitope Load Prediction
To predict neoantigens formed by the somatic variants, we used pVACseq v4.0.9 [329]
with epitope lengths 8-11 and NetMHCpan binding predictions [330].
5.3.8 Statistics
Differences between ctDNA levels were estimated by unpaired t-test from the log
transformed data. Paired t-test was used to evaluate difference between ctDNA levels at
first and second-line treatment in BRAF mutant patients. Differences between the
detection rates were assessed using two-sided Fisher’s exact test. PFS and OS were
estimated using the Kaplan-Meier method, and differences were evaluated using MantelCox tests. Concordance between the clinical response and the ctDNA kinetics was
calculated using the Cohen kappa measure with 95% CI from 1000 bias-adjusted and
accelerated bootstrap (BCa) replications. Statistical difference between baseline and
follow-up ctDNA levels from same individuals were assessed by the Poisson test, using
the minimum and maximum values plus total droplet counts as analytical variables.
Frequencies and percentages by group along with their corresponding P-values of the
chi-squared test are reported in Table S5.1. Multivariate Cox regression analysis was
performed for PFS and OS in Table S5.2. The unpaired two-tailed t-test was used to
compare mutational and neoepitope load between patients that were responders or nonresponders to anti-PD-1 immunotherapy. Pearson correlation was used to determine
correlation between mutational burden and neoepitope load. All statistical analyses were
performed using R version 5.2, GraphPad Prism version 5 and SPSSv22.0. Results were
considered statistically significant at P<0.05.

5.4 Results
5.4.1 Plasma ctDNA detection in melanoma patients commencing systemic therapy
We first evaluated the rate of ctDNA detection in 142 plasma samples collected prior to
treatment initiation (Fig. 1).
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Figure 5.1. ctDNA quantification in melanoma patients prior to commencing systemic therapy.
(a) Plasma ctDNA levels (copies/mL of plasma) in melanoma samples (N=144), stratified by M
status. M1d cases were further subdivided into those with extracranial (EC) and those with brain
only metastases. Percentages denote the frequency of patients with detectable ctDNA. The
geometric mean of ctDNA concentrations is indicated for each group by a dashed red line.
Unpaired t-test P-values of the log-transformed ctDNA levels are indicated. (b) Dot plot diagram
showing ctDNA at baseline in patients treated with immunotherapy (IT) and targeted therapy
(TT). (c) ctDNA detection in patients with BRAF, NRAS, or BRAF/NRAS wild-type tumours
commencing first-line treatment. (d) ctDNA detection at first-line and second-line treatment in
BRAF mutant patients. Red dots represent patients with intracranial disease only at time of
starting therapy.

The ctDNA detection rate was 65% overall, but patients with one or more prominent
visceral metastases (M1c), particularly in the liver, bone and lung, had significantly
higher ctDNA detection rates when compared to those with M1a disease (P=0.002; Figure
5.1A). Similarly, median ctDNA levels were significantly higher in M1c patients compared
with M1a (P=0.001) or M1b (P=0.015). In addition, ctDNA levels in patients with M1d and
extracranial disease were significantly higher compared with M1a disease (P=0.047).
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Notably, none of the ten M1d patients with brain only metastases had detectable ctDNA
(Figure 5.1A), indicating that ctDNA levels are influenced by the site of metastases.
5.4.2 Baseline ctDNA detection prior systemic treatments
We then compared the ctDNA detection rates in plasma collected prior to commencing
treatment with immune checkpoint inhibitors or targeted agents. We observed reduced
ctDNA concentrations and a significantly lower detection rate in patients receiving
immunotherapy when compared to those receiving BRAFi±MEKi (56% vs 76%; P=0.014;
Figure 5.1B).
Due to the difference in ctDNA detection rates between the targeted therapy and
immunotherapy groups, we evaluated whether the mutational target used for ctDNA
analysis influenced these results. Comparison of the detection rate of ctDNA between
mutational targets demonstrated no significant difference between ctDNA levels and
detection rate (geometric mean: 19.2 copies/mL, 67/100, 67%) in patients with BRAF
versus patients with other melanoma associated mutations (geometric mean: 13.7
copies/mL, 26/42, 62%; Figure 5.1C).
To determine if ctDNA levels are influenced by the line of therapy, we compared ctDNA
levels in 21 BRAF mutant patients that received first-line targeted therapy and secondline immunotherapy (Figure 5.1D). This sequence of treatment is commonly used for
BRAF mutant melanoma in Australia. Despite not showing statistical significance, ctDNA
detection rate was lower in patients commencing second-line treatment (81% vs 48%,
P=0.100). This result is likely influenced by the effectiveness of regular radiological
monitoring in identifying disease progression at low tumour burden.
5.4.3 Longitudinal ctDNA monitoring for prediction of response
We further investigated whether ctDNA positivity at baseline and early during the
treatment course were correlated with treatment response. A total of 84 patients with
longitudinal blood collections within 12 weeks of treatment were included and stratified
according to treatment, that is, targeted therapy (N=47) vs immunotherapy (N=37), and
divided into three groups depending on the ctDNA profile during the first 12 weeks of
treatment (Figure 5.2A). Similar to that shown by Lee et al. [217], Group A consisted of
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patients with undetectable ctDNA levels at baseline and during 12 weeks of therapy or
non-significant ctDNA changes. Group B had detectable baseline ctDNA that became
undetectable or significantly reduced during treatment and group C includes patients
that were either ctDNA positive or negative at baseline with static or significantly
increased levels during the first 12 weeks of therapy. Overall, groups A and B represented
patients that showed a biological response, evidenced by undetectable or a significant
reduction in ctDNA levels, and group C was comprised of patients that did not show a
biological response, that is, detectable or non-significant reduction in ctDNA levels.
An 86% observed agreement was found between the best clinical response within 6
months from treatment initiation and the biological response offered by longitudinal
ctDNA monitoring (72/84). Notably, a subset of seven patients without objective
response or unequivocal disease progression, who were treated with either
immunotherapies (N=3) or targeted therapies (N=4), had a biological response. A strong
agreement was found between the biological and the clinical response (Figure 5.2B;
κ=0.798, 95% CI 0.570 to 0.958, N=77, P<0.001), when these seven patients were
excluded from the analysis. Discordance was observed in five patients (5/77, 6%), with
three patients noted to have no detectable or significant decrease in ctDNA levels despite
having clinical progression (PD) in subcutaneous lesions (Patient #170.2 and 755), lymph
nodes (755), muscle (755 and 486) and brain (170.2). The PD lesions observed in patient
170.2 were in the subcutaneous tissue and brain. By contrast, two patients (538 and 493)
were found to have a clinical response to pembrolizumab and dabrafenib/trametinib,
respectively, but no biological response was observed.
We next compared the biological ctDNA response with longitudinal blood collection for a
period of 24 weeks after starting treatment. In this cohort, most patients treated with
anti-CTLA-4 and anti-CTLA-4/PD-1 did not show radiological response to therapy, and
their ctDNA levels remained high (Figure S5.1A and S5.1B). By contrast, 17 of the 21
(81%) patients receiving anti-PD-1 immunotherapy had a partial response (PR) or
complete response (CR; Figure S5.1C). The clinical response rate in the targeted therapy
cohort was also high (41/47, 87%) but a number of these patients (10/41, 24%)
developed resistance and relapsed within the first 24 weeks of therapy, with 9 of them
demonstrating rebounding ctDNA levels (Figure S5.1D).
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Figure 5.2. ctDNA levels early during treatment relative to clinical response. (a) Columns
represent each patient, best clinical response, treatment type, and longitudinal quantitative
ctDNA results. Patients treated with immunotherapy or targeted therapy were stratified into
three profile groups: A=undetectable ctDNA at baseline and during treatment with biological
response, B=detectable ctDNA at baseline that became undetectable during treatment or had a
significant biological response and C=detectable/undetectable ctDNA at baseline that remained
or became detectable during therapy without significant biological response. *Significant
Biological Response. bPresence of only intracranial malignant disease at baseline or at PD. (b)
Concordance between best clinical response at 6 months and biological ctDNA response within
the 12 weeks of treatment. Patients categorised as clinically responders (PR/CR, N=61), patients
with stable disease (SD, N=7), and patients with disease progression (PD, N=16) and, ctDNA
responders (Group A and B; N=69) or non-responders (Group C; N=15) based on their biological
ctDNA response over the first 12 weeks of treatment. Abbreviations: ND=Not detectable;
NSD=Non-significant decrease. (c) Plasma ctDNA levels at baseline and follow-up in patients that
responded to targeted therapy (N=26) and to immunotherapy (N=6). P-values of paired t-tests
are indicated. The geometric mean ctDNA concentration is indicated for each group by a dashed
red line.

We analysed patients with objective clinical response that had detectable ctDNA at
baseline and assessable follow-up samples. Within these groups, ctDNA dropped
significantly by 3-6 weeks in the targeted therapy cohort (N=26, P<0.0001; Figure 5.2C).
In contrast, most patients (67%) who responded to immunotherapy had detectable
ctDNA levels at first follow-up and, only had the significant drop to undetectable levels
on their second follow-up by 12-18 weeks (P=0.004, Figure 5.2C).
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5.4.4 Longitudinal ctDNA monitoring for prediction of survival
We evaluated whether the ctDNA changes during the first 12 weeks of treatment (groups
A, B or C) had prognostic value in patients treated with immunotherapy. For the survival
analysis, patients receiving single-agent immunotherapy ipilimumab (N=8) were
excluded due to their poor response rate and rapid transition into anti-PD-1, which may
confound survival analysis. Clinical characteristics across the three groups were similar
for age, sex, tumour stage, the prevalence of brain metastases and prior lines of treatment
(Table S5.1).
In patients receiving immunotherapy, groups A and B had significantly longer
progression-free survival (PFS) and overall survival (OS) compared to group C (Figure
5.3A and 5.3B). Median PFS for groups B and C was 73 and 5 weeks respectively, but was
not reached for group A. The hazard ratio (HR) was 0.052 (95% CI=0.010 to 0.275,
P=0.0005) for group A and 0.176 (95% CI=0.041 to 0.750, P=0.019) for group B when
compared with group C. There was no statistical difference in the PFS of groups A and B
(P>0.05). Median OS for group B and C were 150 and 24 weeks respectively but was not
reached for group A (Figure 5.3B). The HR was 0.081 (95% CI=0.014 to 0.454, P=0.004)
for group A and 0.190 (95% CI=0.395 to 0.922, P=0.039) for group B when compared
with group C. There was no statistical difference in the OS of groups A and B (HR=0.705,
95% CI=0.134 to 3.693, P>0.05).
In a multivariate Cox regression model, ctDNA kinetics in group C was found to be an
independent predictor of shorter PFS (HR=16.9, 95% CI=2.68 to 106.25, P=0.003) and OS
(HR=22.48, 95% CI=2.75 to 183.69, P=0.004; Table S5.2). Notwithstanding the low
number of samples in Group C (N=3), in patients treated with targeted therapy (Figure
5.3C), group A had longer PFS when compared to compared to group B and C. Median PFS
was 100, 39 and 5 weeks for group A, B and C, respectively. When compared with group
A, the hazard HR was 0.458 (95% CI=0.215 to 0.977, P=0.043) for group B and 0.001
(95% CI=4.548x10-5 to 0.027, P<0.0001) for group C. Despite the differences in the PFS
between these groups, there was no difference between their median OS (Figure 5.3D,
P>0.05). A multivariate Cox regression model, found that ctDNA kinetics in group B is an
independent predictor of decreased PFS (HR=6.65, 95% CI=1.80 to 24.56, P=0.004) and
OS (HR=10.51, 95% CI=1.78 to 62.04, P=0.009; Table S5.2).Due to the low number of
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samples in group C (N=3), these patients were excluded from the analysis. Interestingly,
the prediction significance of ctDNA kinetics was attributed to the presence of patients
with visceral plus brain and brain only patients in the analysis. When excluding group C
patients from the multivariate analysis, ctDNA kinetics between groups was not found to
be an independent predictor of PFS.
5.4.5 Measuring mutational burden using ctDNA
Plasma ctDNA analysis constitutes an attractive approach for real-time assessment of
tumour mutational profile and alleviates caveats associated with tissue biopsies
including tumour heterogeneity. Here, we determined the feasibility of quantifying
mutational load in patient-derived cfDNA. We screened melanoma patients treated with
anti-PD-1 inhibitor as a first- or second-line treatment, with a ctDNA fraction of more
than 7% abundance by ddPCR. Nine patients were selected and dichotomised according
to their best clinical response to therapy, with responders noted as having either a partial
response, a complete response or prolonged stable disease. Non-responders are those
without clinical or objective response and who had progressive disease within 6 months
of treatment initiation. Clinical characteristics for these patients are described in Table
S5.3.
Mutational data were obtained from the nine patients, with the number of mutations
ranging from 1-58 per Mb of DNA (Table 5.1). While patients that responded to anti-PD1 inhibitor had higher tumour mutational burden (TMB) compared to non-responders
(mean: 21 vs 6 per Mb), the difference was not statistically significant (Figure 5.4A).
Nonetheless, our results may be confounded by the small sample size analysed for TMB.
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Figure 5.3. ctDNA levels early during treatment relative to survival. Progression free survival (PFS) and overall survival (OS) curves for patients
treated with immunotherapy (a, b) or targeted therapy (c, d) stratified into the three previously detailed profile groups A, B and C. Cox regression Pvalues, Hazard Ratio (HR) and 95% confidence intervals (CI) are indicated for each plot.
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Table 5.1. Mutational burden and predicted neoepitope load of nine melanoma patients.
Response
Classification

Responders
(R)

NonResponders
(NR)

Sample
ID
MP0104
MP0105
MP0201
MP0302
MP0303
MP0102
MP0103
MP0301
MP0304

Mutational
Burden
(per Mb)
22
2
4
58
22
10
1
1
14

Predicted
Neoantigens
IC50<500nM
1362
131
432
1516
429
439
114
25
469

Predicted
Neoantigens
IC50<50nM
236
32
86
259
57
105
25
3
75

As mutational burden alone did not explain clinical benefit from anti-PD-1 inhibitors, we
hypothesised that the presence of specific tumour neoantigens might explain the varied
dichotomised patients that are likely to benefit from this immunotherapy. To identify
these neoepitopes, the HLA-I phenotype of each patient were identified and the
bioinformatics pipeline for pVACSeq (https://github.com/griffithlab/pVAC-Seq) was
used for neoepitope prediction.
The number of predicted neoepitopes with a binding affinity of IC50<500nM ranged from
25-1516 and was higher in responders (mean = 774) versus non-responders (mean =
262) to immunotherapy (Figure 5.4B). The number of predicted neoepitopes with strong
binding affinity (IC50<50nM) ranged from 3-259 and was similarly higher in responders
compared to non-responders (mean = 134 vs 52, Figure 5.4C). However, the difference in
the number of neoepitopes in these two groups was again not significant (P>0.05).
Nonetheless, the number of neoepitopes correlated with the mutational burden (Figure
5.4D-E). Overall, there was a trend that high neoepitope load was associated with
response to anti-PD-1 treatments. Nevertheless, three of the five responders had
neoepitope loads in the same range as the non-responders, indicating that at a singular
patient level, this parameter alone cannot be used for treatment decisions.
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Figure 5.4. ctDNA as a tumour source for mutational burden analysis. (a) Vertical scatter plot of the difference in the mutational burden (number of
single-nucleotide variants (SNVs per Mb of DNA) in responders (green) and non-responders (red) to anti-PD-1 blockade. Graphs indicating the
difference in the number of low - IC50<500nM (b) and high - IC50<50nM (c) affinity neoantigens in melanoma patients treated with immunotherapy.
Correlation between the mutational burden and neoepitope loads at IC50<500nM (d) and IC50<50nM (e).
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5.5 Discussion
The prognostic value of ctDNA in melanoma patients has been previously shown by
number of studies [13, 16, 187, 217, 331]. In this study, we found ctDNA detectability at
baseline and during treatment course to be a strong predictor of clinical outcome. In
particular, we showed that high levels of ctDNA at baseline and throughout the first 12
weeks of treatment were indicative of poor survival outcome in melanoma patients
receiving first-line immune checkpoint inhibitors as well as on those receiving targeted
therapies. Moreover, patients with undetectable ctDNA at baseline, who remained ctDNA
negative during treatment, have a longer time to progression irrespective of treatment.
Notably, detectability of ctDNA and its resolution during treatment was also associated
with good clinical outcome in patients treated with immunotherapy and targeted
therapies. In addition, we describe for the first time a different ctDNA pattern of response
in targeted therapy and in immunotherapy.
Overall, our findings underscore the suitability of ctDNA as a prognostic biomarker for
the currently available treatments of melanoma patients. Our findings indicate that
ctDNA is most informative as an early indicator of clinical response. In fact, we found a
significant concordance between baseline ctDNA levels and response to first-line
immunotherapy and targeted therapy. The decline in ctDNA levels was found to be highly
concordant with the radiological response to treatment, while increasing ctDNA levels
was correlated with disease progression. These results are supported by previous
findings [217] and further demonstrated the ability of ctDNA to accurately reflect disease
status of patients, making it a valuable surrogate or companion biomarker for patient
surveillance during treatment.
Interestingly, we found a low response rate amidst patients treated with anti-PD-1 plus
anti-CTLA-4, in contrast with that observed in clinical trials [109, 129]. The patients in
our combined immunotherapy cohort had extensive brain metastases and/or
widespread disease, which may have reduced the response rates. Moreover, very few
patients in our cohort were treated with combined immunotherapy, and therefore the
response rates observed here may not necessarily reflect that of previous studies.
We also want to highlight the difference in the rate of ctDNA decay between patients
treated with targeted therapy and immunotherapy. In this study, we observed a delayed
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velocity of ctDNA decay in patients that respond to immunotherapy compared to patients
undergoing targeted therapy. This data reflects the time interval necessary to unleash an
immune response to cancer [332], which needs to be taken as an important consideration
when monitoring response to different types of treatment through a liquid biopsy. The
current treatment approach for melanoma is based on evaluating disease progression,
followed by treatment modification to potentially improve patient outcomes and
discontinue ineffective therapy. Our data suggest that an observation period may be
required prior to conclusive evaluation of therapeutic benefits to immunotherapy and
treatment modification decisions.
While ctDNA was found to be a reliable prognostic and surveillance biomarker, it is not
without limitations. A significant roadblock for ctDNA analysis in this study was the low
detection rate of ctDNA prior to anti-PD-1 and/or anti-CTLA-4 treatment compared with
targeted therapy. As indicated above, most patients with detectable ctDNA have
prominent visceral metastases, particularly to the liver. The variation of tumour cell
turnover at different metastatic sites may have an impact on the detectability of ctDNA.
In addition, the low detection rate may have been affected by the specificity of the assay
used for ctDNA analysis. Aside from our in-house BRAF assays, which have been
previously reported to have high specificity and sensitivity [263], assays for other
mutations have a lower limit of detection due to noise [234]. Differences in assay
threshold may also affect the detection rate of ctDNA in melanoma patients treated with
immune-checkpoint inhibitors. Thus, the site of metastases and the assay specificity of
the mutational target for ctDNA analysis appears to highly influence the variation in the
detection rate observed in this study.
Previous studies have demonstrated the predictive value of tissue-derived mutational
and neoepitope load for immunotherapy response in NSCLC [318, 319] and melanoma
[323]. In this study, we also explored the potential utility of ctDNA for mutational and
neoepitope load analysis in melanoma. Gandara et al. [322] demonstrated the utility of
blood tumour mutational burden as a clinically-actionable biomarker for anti-PD-L1 in
NSCLC. Similarly, our exploratory analysis also demonstrated that whole exome sequence
(WES)-defined molecular analysis for clarifying tumour mutational burden in ctDNA is
possible. In our cohort, mutational load was unable to discriminate between responders
and non-responders to anti-PD-1 inhibitor. Nonetheless, we observed a trend showing
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high neoepitope load in patients that achieved clinical benefit to anti-PD-1 blockade. The
small sample size was not sufficient to discriminate between responders and nonresponders to immunotherapy. These findings may be confounded by the small sample
size mostly consisting of patients with high levels of ctDNA (>7% frequency abundance).
WES analysis imposed the need to select for patients with high ctDNA fraction, which
excluded most samples in our cohort. On the other hand, mutational burden derived from
targeted sequencing has been previously shown to be sufficient for stratifying responders
and non-responders to immunotherapy [322]. Thus, a targeted approach, with the
addition of unique molecular identifiers (UMI), may be more fitting for ctDNA mutational
burden analysis, as it will be able to control for PCR errors and allow interrogation of
variants at low allelic fraction (<1%).
In conclusion, ctDNA has significant clinical value as a biomarker of prognosis and
therapeutic response for melanoma. Nonetheless, limitations inherent to ctDNA analysis
need to be clearly defined and thoroughly addressed prior to its implementation in the
clinic.
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5.8 Supplementary Material

Figure S5.1. Kinetics of ctDNA decay. Time course of biological response for patients undergoing first or second-line treatment with (a) anti-CTLA-4
(N=8), (b) anti-CTLA-4 plus anti-PD-1 (N=8), (c) anti-PD-1 (N=21) or (d) targeted therapy (BRAF/MEKi) (N=47). Solid lines in green, orange and red
denotes treatment responders, stable disease and non-responders, respectively. Solid lines in green with red symbol represents patients that
developed resistance to targeted therapy.
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Figure S5.2. Flow chart showing group of samples included in the analyses.
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Table S5.1. Clinical characteristics at baseline of the melanoma patients categorised in Groups A, B, and C included in the survival analysis (N=76).

Variable
Age
≤65
>65
Gender
Female
Male
M Classification
M1a/M1b
M1c/M1d
Brain metastasis
Yes
No
Brain only metastasis
Yes
No
ECOG status
0
1,2,3
Not available
LDH levels
Normal
Abnormal
Not available
Prior lines of therapy
Yes
No
BRAF mutational status
BRAF Mutant
BRAF WT
N/A: not applicable.

Group A
N=14 (%)

Immunotherapy
Group B Group C
N=8 (%) N=7 (%)

Total
N=29 (%)

P-value
(A/B/C)

Group A
N=11 (%)

Targeted Therapy
Group B Group C
N=33 (%) N=3 (%)

Total
N=47 (%)

P-value
(A/B/C)

5 (36)
9 (64)

6 (75)
2 (25)

3 (43)
4 (57)

14 (48)
15 (52)

0.196

5 (45)
6 (55)

18 (55)
15 (45)

2 (67)
1 (33)

25 (53)
22 (47)

0.775

3 (21)
11 (79)

1 (12)
7 (88)

4 (57)
3 (43)

8 (28)
21 (72)

0.120

5 (45)
6 (55)

10 (30)
23 (70)

1 (33)
2 (67)

16 (34)
37 (66)

0.655

9 (67)
5 (36)

2 (25)
6 (75)

1 (14)
6 (86)

12 (41)
17 (59)

0.049

2 (18)
9 (82)

9 (27)
24 (73)

1 (33)
2 (67)

12 (26)
35 (74)

0.794

3 (21)
11 (79)

2 (25)
6 (75)

1 (14)
6 (86)

6 (21)
23 (79)

0.873

6 (55)
5 (45)

5 (15)
28 (85)

1 (33)
2 (67)

12 (26)
36 (74)

0.032

2 (14)
12 (86)

8 (100)

7 (100)

2 (7)
27 (93)

N/A

2 (18)
9 (82)

33 (100)

3 (100)

2 (4)
45 (96)

N/A

9 (64)
3 (22)
2 (14)

3 (37.5)
3 (37.5)
2 (25)

3 (43)
3 (43)
1 (14)

15 (52)
9 (31)
5 (17)

8 (73)
1 (9)
2 (18)

16 (48)
5 (15)
12 (36)

2 (67)

N/A

7 (50)
1 (7)
6 (43)

2 (25)
4 (50)
2 (25)

1 (14)
3 (43)
3 (43)

10 (34)
8 (28)
11 (38)

8 (73)

6 (43)
8 (57)

4 (50)
4 (50)

1 (14)
6 (86)

11 (38)
18 (62)

0.316

6 (43)
8 (57)

2 (25)
6 (75)

1 (14)
6 (86)

9 (31)
20 (69)

0.373

N/A

1 (33)

26 (55)
6 (13)
15 (32)

3 (27)

13 (39)
13 (39)
7 (22)

1 (33)
2 (67)

21 (44)
14 (30)
12 (26)

1 (6)
10 (94)

2 (6)
31 (94)

3 (100)

3 (6)
44 (94)

11 (100)

33 (100)

3 (100)

47 (100)

N/A

N/A

N/A

N/A
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Table S5.2. Multivariate Cox proportional-hazards regression analysis for associations between ctDNA levels and survival.
Group A/B/C Immunotherapy
Progression free survival
Variables

Group A/B Targeted Therapy

Overall survival

Progression free survival

Overall survival

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (≤65 vs. >65)

0.34 (0.73 - 1.61)

0.175

0.51 (0.11 - 2.48)

0.407

1.41 (0.64 - 3.05)

0.388

1.82 (0.68 - 4.87)

0.228

Gender (female vs. male)

0.87 (0.21 - 3.69)

0.851

10.02 (1.27 - 78.71)

0.028

1.17 (0.52 - 2.62)

0.694

0.87 (0.31 - 2.39)

0.792

M Classification (M1a/b vs. M1c/d)

0.95 (0.19 - 4.62)

0.956

5.94 (0.63 - 55.78)

0.119

0.80 (0.32 - 2.02)

0.650

1.24 (0.37 - 4.19)

0.720

Brain metastasis (yes vs. no)

3.76 (0.71 - 19.85)

0.118

1.95 (0.33 - 11.49)

0.459

3.05 (1.09 - 8.54)

0.034

5.25 (1.34 - 20.50)

0.017

Brain only metastasis (yes vs. no)

-

-

-

-

14.20 (1.48 - 136.34)

0.021

Prior lines of therapy (yes vs. no)

0.84 (0.08 - 8.05)

0.881

0.12 (0.004 - 3.73)

0.228

0.64 (0.15 - 2.67)

0.542

0.23 (0.02 - 2.07)

0.191

BRAF mutational status (mut vs. WT)

1.45 (0.13 - 15.48)

0.758

6.32 (0.21 - 189.11)

0.287

-

-

-

-

0.004
-

1
10.51 (1.78 - 62.04)
-

0.009
-

ctDNA levels
ctDNA kinetics group
Group A vs.
Group B
Group C

1
1.91 (0.32 - 11.22) 0.471
16.90 (2.68 - 106.25) 0.003

1
0.98 (0.13 - 7.17)
0.991
22.48 (2.75 - 183.69) 0.004

10.04 (1.27 - 79.27) 0.029

1
6.65 (1.80 - 24.56)
-
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a

Pembrolizumab

PR

Yes (Ipilimumab)

25/08/2014

29/08/2016

105

MP0105

BRAF WT

Pembrolizumab

CR

Yes (Ipilimumab)

10/02/2015

29/12/2017

150

MP0201

BRAF Mut

Pembrolizumab

CR

No
(Radiation Therapy)

5/08/2016

27/02/2018

82

x

x

MP0303

BRAF Mut

Pembrolizumab

PR

No

15/09/2017

Ongoing

90a

x

x

MP0302

BRAF Mut

Pembrolizumab

SD

No

13/12/2017

31/05/2018

24

MP0102

BRAF WT

Pembrolizumab

PD

No

10/12/2015

12/02/2016

9

MP0103

BRAF Mut

Pembrolizumab

PD

No

13/05/2016

4/07/2016

7

MP0301

BRAF WT

Pembrolizumab

PD

No

11/06/2015

18/09/2015

14

MP0304

BRAF WT

Pembrolizumab

PD

No

03/04/2017

25/05/2017

7

Weeks in treatment as of 31/08/2019

Sub-cutaneous

BRAF Mut

Pelvic Region

MP0104

Pancreas

Length of
Treatment
(wks)

Mesentery

Treatment
Completion
or Latest Clinic

Lymph Node

Start of
Treatment

Lung

Previous
Immunotherapy

Liver

Best
Clinical
Response

Bone

Treatment

Brain

BRAF
Status

Adrenal

Sample
ID

Oropharynx

Abdomen

Table S5.3. Clinical characteristics of melanoma patients in this pilot cohort.

x
x

x
x

x

x
x
x

x

x

x

x

x

x
x
x

x

133
Table S5.4. Demographic, clinicopathologic, and treatment characteristics of included samples.
All samples
Immunotherapy
Targeted Therapy
Variable
N=72 (%)
N=70 (%)
N=142
Age
20-49
50-69
70-99

11 (15)
38 (53)
23 (32)

20 (29)
31 (44)
19 (27)

18 (25)
54 (75)

25 (36)
45 (64)

16 (22)
7 (10)
31 (43)
18 (25)

15 (21)
6 (9)
32 (46)
17 (24)

30 (42)
20 (28)
22 (30)

70 (100)

Sex
Female
Male

M Classification
M1a
M1b
M1c
M1d

Mutational Status
BRAF Mutant
NRAS Mutant
Others

Treatment
Anti-PD1 inhibitor
Pembrolizumab
Nivolumab
Anti-CTLA-4 inhibitor
Ipilimumab
Anti-PD-1
plus
anti-CTLA-4
inhibitor
Ipilimumab/Nivolumab
BRAFi
Vemurafenib
Dabrafenib
BRAFi plus MEKi
Dabrafenib/Trametinib
Vemurafenib/Cobimetinib

40 (56)
1 (1)
12 (17)

19 (26)
4 (6)
1 (1.5)
64 (91)
1 (1.5)
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Table S5.5. Specificity of ddPCR assays.
Healthy controls
Assay
Maximum false positive concentration (copies/mL)
Positive Negative
BRAF V600E2

1

12

1

BRAF K601E

3

7

2

BRAF L597Q

0

16

0

NRAS Q61R

7

24

9

NRAS G12D

4

6

3

NRAS G13D

4

6

5

GRM3 E538K

0

10

0

GRM3 S491L

6

12

6

FLT1 E011K

3

7

9

TP53 R158H

1

9

2
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CHAPTER 7. GENERAL DISCUSSION AND FUTURE DIRECTIONS
Plasma ctDNA is currently considered a promising biomarker of disease status for
metastatic cancer [275, 316, 358]. In this context, the studies in this thesis evaluated the
validity of ctDNA analysis across the whole spectrum of metastatic melanoma
management: i) molecular profiling prior to therapy initiation to aid targeted therapy
selection (Chapter 3), ii) prognostic and predictive potential of baseline ctDNA levels
(Chapter 4), iii) monitoring response to treatment (Chapter 5) and iv) detection of
disease progression (Chapter 6) (Figure 7.1).

Figure 7.1. Applications of ctDNA analysis during metastatic melanoma management.

Detection of ctDNA requires highly sensitive and specific assays, especially in patients
with low tumour burden. In melanoma, multiple studies have relied on a single mutation
targeted approach for ctDNA analysis using droplet-based PCR systems, particularly
ddPCR and BEAMing. Both methods generally target a single mutation at a time and have
been shown to have a substantially high analytical sensitivity compared to other ctDNA
detection assays [359]. Direct comparison of ddPCR and BEAMing indicated a high
agreement (κ = 0.87; 95% CI, 0.81–0.93) [360]. Therefore, the use of ddPCR for ctDNA
detection through these studies is in line with current best practice.
Given that a large proportion of melanomas carry hotspot mutations in BRAF or NRAS
[74], the use of single mutation target has been exploited for tracking disease burden over
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time. For individuals that do not harbour these common variants, sequencing of tumour
samples is necessary to identify mutational targets for ctDNA analysis by ddPCR [234].
In Chapter 2, we described an optimal and reproducible cfDNA extraction [249-251] and
testing protocol that enables sensitive and specific detection and quantification of ctDNA
from plasma samples. This ddPCR assay has been the primary approach used in the
studies comprising this thesis.
In addition to the sensitivity of each assays, it is also apparent that pre-analytical factors
can significantly affect ctDNA detection rate [243, 244, 355, 361]. Importantly, ctDNA
studies should report on the conditions in plasma separation and storage, transport and
cfDNA extraction to allow comparison to be made between studies. To provide robust
and comparable results, Chapter 2 outlines the use of optimal blood collection tubes [246]
and the most efficient column-based cfDNA extraction method, previously vetted by the
CANCER-ID consortium study. The study compared the extraction efficiency of 6 different
cfDNA extraction kits from a total of 17 independent laboratories and concluded that the
QIAamp Circulating Nucleic Acid kit showed the highest recovery, independent of the
blood collection tube used [247].
Using a multiplex BRAF assay for ddPCR, the study in Chapter 3 demonstrated a high
degree of concordance between standard-of-care tumour-based BRAF mutation profiling
and plasma-based testing. The positive agreement was found to be 78% and an overall
agreement of 88%, supporting the results of multiple other studies [216, 218, 224, 225,
362]. Nevertheless, it is important to note that undetectable mutant BRAF ctDNA, without
prior knowledge of the patients’ BRAF status, does not preclude the possibility that the
variant is either absent in the tumour or that there was an insufficient amount of ctDNA
present in the specimen. This has been recognised as a major limitation for the use of
ctDNA for tumour genotyping [276]. Accordingly, while the FDA and the EMA approved
the ctDNA test for detection of the EGFR p.T790M resistance mediating mutation in
(NSCLC), undetectable ctDNA results have to be followed by the use of a tissue biopsy to
confirm the absence of the mutation [276]. In line with this recommendation, if BRAF
genotyping is to be pursued through ctDNA profiling, a negative result will need
confirmation on a tumour sample before a patient can be deemed BRAF-mutant negative
and potential exclusion from BRAF targeted therapies.
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Chapter 3 also presents an attempt to model the potential economic benefit of BRAF
profiling through cfDNA testing. We calculated that savings of at least $36,238 per annum
could be incurred if BRAF cfDNA testing was performed instead of tumour biopsy
analyses, representing a reduction of 22% on the overall expense of BRAF testing. These
results support the inclusion of ctDNA analysis to establish tumour genotype prior to
treatment with targeted therapies is to be considered.
The main advantage of cfDNA analysis is that it offers an alternative route for assessing
BRAF status in cases where metastases are widespread and tissue biopsy is not possible
or does not yield sufficient material for testing. Additionally, the high prevalence of
activating BRAF mutations in colorectal, thyroid, and ovarian cancers [289], as well as
clinical trials with targeted therapies [290, 291], enable its use beyond melanoma.
Moreover, BRAF mutation tests may become relevant to other cancer types that receive
regulatory approval for the use of BRAF inhibitor therapy.
Despite the encouraging results presented in this thesis, obtaining a tissue sample for
molecular profiling is not typically a major obstacle in metastatic melanoma, as biopsies
are commonly performed to confirm the disease. Therefore, although ctDNA testing for
BRAF detection is clinically valid, in practice it will only be useful and cost-effective in a
minority of cases. For example, for cases where a tumour biopsy will involve a very
invasive procedure, the patient has significant comorbidities and there is a need for a
rapid tumour turnaround for treatment decision [219]. Similarly, it is not uncommon that
FNA procedures yield insufficient or unsuitable tumour material for genotyping, and in
such cases, a rapid and minimally invasive ctDNA testing may provide critical information
to inform treatment course.
Limited economic studies have investigated the use of this liquid biopsy in oncology and
most of them have shown only a moderate to no economic benefit [363-365]. These
results underscore the reality that the implementation of ctDNA analysis into clinical
practice necessitates thorough cost-effectiveness calculations to further support its
clinical utility [366]. The economic benefit must be related to each specific context of use
for ctDNA analysis in the management of cancer, i.e. prognostication for early
intervention, genotyping for treatment selection or disease monitoring. Notwithstanding
the cost associated with performing a liquid biopsy needs to be outweighed by the
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benefit, which for most applications would be ultimately an improvement in survival.
However, survival benefits also depend on the efficacy of the associated therapeutic
intervention. Thus, it is only through careful study designs and/or large clinical trials that
incorporate ctDNA results to inform treatment decisions, that the health economic
benefit of liquid biopsies can be accurately assessed and their regulatory approval can
move forward.
Currently, treatment selection and monitoring a patient’s disease course during therapy
are considered important priorities for melanoma management. It is in this context that
a liquid biopsy may have the biggest impact. Once the mutation profile has been
identified, first-line selection treatment by the medical professionals involves accounting
for multiple factors such as median tumour size, LDH levels, BRAF status, presence of
brain metastases and comorbidities that must be carefully considered [136, 309, 310].
In Chapter 4, we analysed the ability of ctDNA to assist with treatment selection and
patient stratification. Similar to previous studies, we found that high ctDNA levels are
associated with poorer clinical outcomes [12, 15, 187, 193], while a low baseline ctDNA
level correlated with tumour shrinkage on radiology [213] and longer PFS in melanoma
patients treated with immunotherapies [14]. By contrast, Lee et al. showed that a decline
in ctDNA level during treatment, but not low concentration at baseline, was predictive of
longer PFS and OS [217]. This may be due to the inclusion of a large proportion of patients
receiving immunotherapy in the second-line setting.
Indeed, we found that the predictive value of ctDNA was lost in the second-line treatment
setting, particularly in patients failing first-line targeted therapy. Importantly, these
findings were validated using an independent cohort of patients with samples collected
and analysed in laboratories of collaborators in Sydney and Melbourne. Diverse factors
arising at disease progression including the presence of brain metastases and the
decreased response to second-line therapy may limit the prognostic value of ctDNA in
pre-treated patients. Therefore, the prognostic potential of ctDNA must be taken with
caution in this population. Future studies evaluating ctDNA detectability in relation to
previous systemic therapy and anatomical tumour location are also necessary. Moreover,
there is a need to understand the origin of ctDNA and the cellular dynamics that govern
ctDNA production and shedding [367, 368].
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A novel finding of the study described in Chapter 4, was the observation that patients
with high pre-treatment ctDNA levels had better outcomes if treated with the
combination of anti-CTLA-4 and anti-PD-1 as first-line therapy. Although ctDNA levels
correlate significantly with tumour burden [16, 235], multivariate analyses in previous
studies have shown ctDNA to be a stronger and independent predictor of survival than
tumour burden [201, 211, 212, 217, 235]. In this context, our results suggest that more
aggressive combination treatment will be particularly beneficial to those patients with
high ctDNA levels. On the other hand, patients with low or undetectable ctDNA may be
treated with anti-PD-1 monotherapy, which is associated with less adverse events [369,
370]. However, we should note that the observation regarding patients with high ctDNA
levels benefiting from combination immunotherapy, was the result of a post-hoc analysis
combining both cohorts. Therefore the study was not appropriately designed or powered
to strongly reaffirm this conclusion. A prospective clinical trial is needed to confirm our
observations and validate the use of ctDNA to guide immunotherapy selection.
In Chapter 5, the study defines that decreasing ctDNA levels early during treatment is a
strong predictor of clinical outcome. In particular, high levels of ctDNA prior to treatment
and early during therapy were indicative of poor survival outcome, while patients with
undetectable ctDNA at baseline had a longer time to progression irrespective of
treatment. These results are supported by previous findings [214, 215, 217, 371] in
patients treated with immunotherapy and further demonstrated the capacity of ctDNA to
accurately monitor treatment response and predict clinical outcome in a large cohort of
melanoma patients. These findings underscore the suitability of ctDNA as a prognostic
biomarker for the currently available treatments of melanoma patients. Moreover, the
ability of undetectable or decreasing ctDNA levels to accurately distinguish between true
progression or pseudoprogression has also been investigated [218]. This ambiguous
pattern of response, described as an initial increase in size of tumour lesions followed by
a delayed partial response, can hinder accurate report of response in patients treated
with immunotherapies [372]. In this setting, ctDNA can provide critical clinical
information.
The need of ctDNA analysis beyond BRAF and NRAS mutations becomes critical for
melanoma subtypes other than cutaneous since they are known to carry different driver
mutations. For example, acral and mucosal melanomas are known to carry large

156
proportions of KIT and NF1 mutations [373], which are not restricted to singular
hotspots. In addition to point mutations, acral and mucosal melanomas are commonly
associated with copy number alterations. A study monitoring copy number alterations in
acral and mucosal cfDNA, found that plasma copy number ratio was correlated with
clinical response or progression [374]. Uveal melanomas carry mutually exclusive
activating mutations in GNAQ, GNA11, PLCβ4, and CYSLTR2, accounting for more than
90% of all uveal patients [375-377]. Various studies have utilised these ctDNA mutations
to track uveal melanoma evolution and monitor treatment response [378, 379].
The increased number of therapies available to treat melanoma requires the stratification
of patients into appropriate treatments, stressing the importance of regular monitoring
for timely detection of disease progression and adjustment of treatment. Current clinical
surveillance and monitoring are performed by regular blood tests and expensive imaging
technologies, which are utilised for efficient detection of progressive metastatic disease.
The results presented in Chapter 6 revealed that ctDNA was not reliable for the detection
of disease progression when compared with imaging technologies. We found that in 47%
of the cases, ctDNA failed to detected disease progression. Our results are, in contrast
with other studies indicating a high ctDNA detection rate at the time of progression (51%
and 100%) and that an increasing ctDNA level is pre-emptive of clinical progression, with
a calculated lead time of 25 and 21 weeks [224, 225]. Furthermore, Váraljai et al.
described that in 86% of the 36 melanoma patients that did not show response to
systemic treatment, ctDNA increase preceded radiological progression with an average
lead-time window of 3.5 months [347].
A few factors that could explain the lower ctDNA detection rate at progression reported
in this thesis must be mentioned. Firstly, the studies defined above are comprised of
smaller cohorts that used BEAMing technology for ctDNA detection [224, 225].
Nevertheless, previous studies indicated that BEAMing has the same level of sensitivity
as ddPCR [360]. Secondly, and possibly the critical point, previous studies have compared
ctDNA to CT scan-based progression by RECIST. On the other hand, PET scans are the
modality of choice for disease monitoring in Australia and the one used in our studies. Of
note, published studies have shown that CT scans are less sensitive than PET scans for
detection of metastatic lesions [380, 381]. Thirdly, the ability of ctDNA to detect
progressive disease should be described by a statistically significant increase in ctDNA
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copies. While this point is controversial and some researchers have suggested to perform
a t-test of the triplicate results, we chose to do a Poisson test, in line with the nature of a
ddPCR quantification [382]. Herbreteau et al. [216] was the first study to calculate the
significance of changes in ctDNA levels using Poisson analysis. Similarly, we have
developed a method in Chapter 4 and Chapter 6 that quantifies significant changes in
ctDNA levels. Ultimately, this study highlights the need to develop specific criteria when
evaluating response or progression by changes in ctDNA levels.
Previous studies by our group and others have shown that ctDNA correlates with tumour
size [12, 14, 209, 210] and more strongly with MTB [235]. However, we observed that
ctDNA levels did not correlate with MTB at the time of progression compared to the
analysis at baseline (Figure 6.4). This finding may support the observation in Chapter 4
that ctDNA levels at the time of starting second-line treatment, i.e. at progressive disease
to first-line therapy, fail to accurately provide prognostic information. Notably, both
studies were evaluated in the context of targeted therapies as first-line treatment,
underscoring the need of additional studies investigating how the pathological state of
the tumour and resistance mechanisms to MAPK inhibition may affect ctDNA release. In
this context, melanomas might undergo metabolic reprogramming at the time of
progression to therapy [383] and important changes in the microenvironment of the
tumour lesions might reduce the shedding of ctDNA into the bloodstream.
Across all the studies in this thesis, we highlighted an important limitation of ctDNA
analysis: the lack of or limited ctDNA shedding in patients with disease restricted to the
brain. This represents a critical issue, as current studies have shown that a high
proportion of BRAF mutant patients that progress to first-line targeted therapy present
with brain metastases [302], with 20% of patients presenting only intracranial
progression [384], often contributing to death [308, 385]. Given that brain metastases
have been reported to shed less ctDNA into the bloodstream [192, 300], the large
proportion of disease progression within the brain may contribute to the limited
predictive value of baseline ctDNA and the low ctDNA detection rate in patients with
intracranial disease only. Notably, in the case of brain metastatic lesions, ctDNA can be
found in the cerebrospinal fluid providing an alternative source for liquid biopsies [282,
344]. However, the complexity and invasiveness of lumbar puncture can be a significant
challenge for its routine use in the clinical environment.
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Most studies of ctDNA in melanoma have mainly monitored singular specific mutations
using highly sensitive targeted assays. However, the use of a limited number of variants
in these studies may have hampered our ability to capture the full genetic heterogeneity
present in melanoma tumours. Moreover, it is critical to notice that promoter mutation
targets, such as TERT, have been observed to be under-represented in cfDNA fractions
[16, 257]. Therefore, the analysis of multiple mutations in the same sample could
significantly increase ctDNA detection levels. The recent development of next-generation
sequencing panels that target melanoma-specific mutations has previously been shown
to derive a reliable concordance of mutations between tumour tissue and blood samples
[234, 386]. The continuous development of these assays will continue to support the
suitability of ctDNA analysis for genetic profiling, especially in patients that do not carry
a primary BRAF mutation.
A major limitation on our approach for ctDNA analysis is the use of targeted assays,
commonly restricted to one mutation per patient. The use of these assays is important
when identifying variants associated with response to drugs, such as BRAF in melanoma
[74] or EGFR in non-small cell lung cancer [387]. The common use of this oncogenic driver
mutation has been described as reliable and stable in ctDNA, with relapsing tumours
maintaining their reliance on these key oncogenic drivers [388]. Moreover, we employed
a tumour-informed approach to determine a key mutation to track disease in patients
with BRAF WT melanomas. However, it is possible that factors such as clonality and
oncogenic dependence may affect their frequency abundance in the tumours and
therefore their concentration in plasma. For example, the development of clonal
evolution with the rise of secondary mutations that mediate resistance is affected by
treatment with targeted agents [13] and cfDNA can accurately reveal different sub-clonal
responses to therapy [389] and escape mechanisms such as BRAF amplification [234].
The analysis of multiple variants will not only enable a more accurate disease assessment
but also increase our ability to detect tumoral DNA. Recently, the development of genomic
technologies has enabled the testing and monitoring of multiple tumour-specific
mutations in a single assay.
The MassArray System, which utilises mass spectrometry to accurately measure PCRderived amplicons, is also emerging as a viable alternative approach for multiplexing
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different mutational targets for ctDNA detection and monitoring [188, 234].
Nevertheless, each of the targets remains constrained to single mutational changes. On
the other hand, targeted sequencing can be used to study small regions, such as,
individual exons, or a larger number of loci, expanding our ability to detect multiple genes
of interest [194-197].
Analysis of ctDNA using targeted NGS requires incorporation of UMIs, which enable error
suppression and detection of low frequency mutations [390]. Nevertheless, the high
cfDNA input required, overall cost and lack of standardisation of the analysis pipelines
associated with these technologies, limit their use to the research settings. Current
studies are exploring the use of these assays in various tumour types and future cost
reductions and validations will enable its implementation in ctDNA detection [391].
Beyond mutational analysis on ctDNA, the development of tests such as CancerSEEK that
combine protein with genetic biomarkers has the potential to increase sensitivity [392],
and may significantly increase the detection rate of residual disease and pathological
progression. Furthermore, others studies have reported on multiparametric assays that
include supplementary cancer biomarkers, such as metabolites, mRNA transcripts,
miRNAs or methylated DNA sequences, can increase the detection rate and help to
accurately identify malignancy from a single blood sample [236].
Altogether, ctDNA analysis has a unique place in the management of melanoma. This
minimally invasive modality can rapidly determine the mutation status prior to
treatment initiation, serve as a prognostic biomarker in the first-line therapy setting and
indicate response early during therapy. However, here we show that this liquid biopsy
only detects disease progression in half of the patients when compared to sensitive
imaging technologies and has no prognostic value in the second-line setting.
Studies such as the ones presented in this thesis are important to inform design and
support the development of randomised ctDNA-based interventional clinical trials.
Currently, multiple clinical trials aim at validating the role of ctDNA as a predictive
biomarker across different tumour types and status of disease [393]. Notably, the
MELCIRC trial (NCT02862743) is currently investigating the concordance between
mutations in ctDNA and tumour tissue, as well as the prognostic impact of the ctDNA
genetic profile on survival. Importantly, the phase II CAcTUS (NCT03808441) trial aims
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to evaluate whether ctDNA can aid effective switching from targeted to immune therapy
based on ctDNA decline, early during treatment.
Interest in ctDNA has been increasing during the last decade, especially in the oncology
setting. However, there is a crucial need to increase the consistency between the
protocols used in handling the sample and the techniques used for analysis and reporting
the results. The research presented here stresses the need to develop a uniform and
standard template for plasma isolation and storage, ctDNA analysis and interpretation of
results. Such protocol will allow for the easy integration of this biomarker into clinical
trials by providing clear rules on the optimal pre-analytical steps and ctDNA
quantification platforms. In addition, strict collection windows should be applied in order
to make head-to-head comparison between ctDNA and imaging techniques possible. The
use of ctDNA in melanoma should follow the path of other malignancies such as the recent
ctDNA applications in colorectal cancer whitepaper [394]. Ultimately, the growing body
of work and evidence in the expanding field will clear the way for implementing ctDNA
analysis into routine clinical management [395] and improve cancer care through
precision oncology.
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